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SYSTEMS AND METHODS TO AFFECT 
ANATOMICAL STRUCTURES 
RELATED APPLICATION 
This application claims, under 35 U.S.C. §119(e), the 
benefit of U.S. Provisional Application Ser. No. 61/117,399, 
filed 24 Nov. 2008, the entire contents and substance of 
which are hereby incorporated by reference as if fully set 
forth below. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with U.S. Government support 
under Grant No. EEC-9731643 awarded by the National 
Science Foundation, Grant No. 1 ROI AR051336-01 
awarded by the National Institutes of Health, Grant No. 
W81XWH-08-l-0704 awarded to the Center for Advanced 
Bioengineering for Soldier Survivability through the 
Department of Defense. The U.S. Government has certain 
rights in the invention. 
TECHNICAL FIELD OF THE INVENTION 
The various embodiments of the present disclosure relate 
generally to systems and methods to affect anatomical 
structures. More particularly, the various embodiments of 
the present disclosure are related to systems and methods to 
regenerate bone. 
BACKGROUND OF THE INVENTION 
2 
In addition, allograft bone grafting is associated with a high 
rate of complications and late fractures as well as a risk of 
disease transmission. The high failure rate of allografts is 
largely attributable to the inability of the graft to revascu-
larize and remodel. Ceramic and polymer based bone graft 
substitutes have recently been introduced and are being used 
frequently. But, ceramics tend to be brittle, and polymers 
suffer from limited bioactivity and strength and may need to 
be supplemented with osteogenic cells and growth factors. 
10 Tissue engineering research has focused on therapeutic 
strategies for repairing bone defects by the delivery of 
biological agents along with biodegradable scaffolds. Both 
two- and three-dimensional scaffolds have been designed to 
provide a template for bone repair. Though the focus has 
15 been to create three-dimensional scaffolds having adequate 
strength to support in vivo loading, most scaffolds do not 
provide an optimal environment for cellular function, and 
suffer from slow resorption kinetics. Moreover, exogenous 
cells delivered at the center of these scaffolds in vivo may 
20 not survive due to the initial lack ofvascularity at the defect. 
Thin, two-dimensional membranes have been used for bone 
repair by placing them along the periosteal surface to 
demarcate the osseous from the non-osseous region. Though 
this technique (called guided bone/tissue regeneration) has 
25 been highly successful in the dental field for bone regen-
eration, it has not been quantitatively evaluated for the load 
bearing case of long bone defects. 
Accordingly, there is a need for improved bone grafting 
techniques that promote bone regeneration by facilitating 
30 cellular and vascular ingrowth into the defect space. It is to 
the provision of such improved systems and methods for 
regenerating bone that the various embodiments of the 
present invention are directed. 
BRIEF SUMMARY OF THE INVENTION 
The various embodiments of the present invention are 
directed to systems and methods to affect anatomical struc-
tures. More particularly, the various embodiments of the 
Approximately 2.2 million bone grafting procedures are 
performed worldwide to repair musculoskeletal defects, 35 
with approximately 500,000 bone grafting procedures being 
performed in the U.S. alone. Such musculoskeletal defects 
often result in pain and limited mobility, and therefore 
significantly impact the quality of life of affected individu-
als. 40 present invention are directed to systems and methods to 
regenerate bone. One aspect of the present invention 
includes a system for affecting an anatomical structure, 
comprising: a nanofiber mesh configured to substantially 
conform to an anatomical structure; and an active agent. In 
Bone is one of the few adult tissues with the capacity for 
true self-healing. Unlike soft tissue injuries, which generally 
result in the formation of scar tissue, bone healing concludes 
with the actual regeneration and reconstitution of the injured 
tissue, including the biochemical and biomechanical prop-
erties. 
The need for bone regeneration arises in cases of bone 
loss due to trauma, tumor resection, or disease. Traditional 
orthopedic practice relies on the ability of a surgeon to drill, 
cut, ream, and realign bone. The success of these procedures 
requires technical skill and well-designed hardware. In a 
majority of cases, this is sufficient for healing, due largely to 
the remarkable capacity of bone for self-regeneration. Cer-
tain fractures and bone defects, however, require additional 
bone augmentation. The current procedures for bone aug-
mentation include autologous and allogenic bone grafting, 
and more recently, ceramic and composite substitutes for 
bone grafts. 
The clinical gold standard for bone regeneration has been 
autologous bone grafting, as it provides osteogenic cells and 
osteoinductive factors for bone healing. Though autologous 
bone grafting has been successful in many cases, it has 
significant disadvantages including limited graft material 
and morbidity of the donor site. These limitations have led 
45 one embodiment, the system can further comprise a carrier 
substance, such as a hydrogel. According to such embodi-
ments, at least a portion of the nanofiber mesh defines a 
fillable space, and the carrier substance can be disposed 
within the fillable space, to substantially fill the space. The 
50 nanofiber mesh can have an average pore size of less than 
about 100 micrometers, and the nano fiber mesh can further 
comprise a plurality of macropores. 
In one embodiment of a system for affecting an anatomi-
cal structure, the active agent can comprise at least one 
55 member of the transforming growth factor-beta (TGF-~) 
superfamily, such as bone morphogenetic protein (BMP). In 
an exemplary embodiment of the present invention, the 
system for affecting an anatomical structure is used on a 
bone, and the carrier substance comprises alginate or a 
60 derivative thereof, the at least one member of the transform-
ing growth factor-beta (TGF-~) superfamily comprises a 
bone morphogenetic protein (BMP). In another embodi-
ment, the active agent can comprise a plurality of cells, such 
as mesenchymal progenitor cells. 
to increased use of allograft bone as a substitute for autolo- 65 
gous bone. Allograft bone, however, is inferior to autologous 
bone due to its reduced biological activity after processing. 
Another aspect of the present invention includes a method 
for affecting an anatomical structure, comprising: adapting a 
nano fiber mesh to an anatomical structure of a subject so that 
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the nanofiber mesh substantially conforms to the anatomical 
structure, wherein at least a portion of the nanofiber mesh 
defines a fillable space; and flowing a carrier substance into 
the fillable space, wherein the carrier substance comprises an 
active agent, and wherein at least a portion of the carrier 5 
substance is disposed within the fillable space. The nano fiber 
mesh can have an average pore size of less than about 100 
micrometers. 
FIGS. 7A-C provide (A) a SEM image at low (lOOOx) 
magnification; (B) a SEM image at high (7000x) magnifi-
cation; and (C) a nanofiber diameter histogram. 
FIGS. SA-D demonstrate sample cellularity through DNA 
quantity for cells cultured on (A) tissue culture plates and 
(B) nanofiber meshes. To compare the cellularity on nano-
fiber meshes with that on tissue culture plates, the data was 
plotted again for (C) hMSCs and (D) hAFS cells. (*-sig-
nificantly different than the other cell type at same time The carrier substance can comprise a hydrogel, and the 
carrier substance can further comprise the active agent. In 
one embodiment, the active agent can comprise at least one 
member of the transforming growth factor-beta (TGF-~) 
superfamily. In an exemplary embodiment of the present 
invention, the anatomical structure comprises a bone, the 
carrier substance comprises alginate or a derivative thereof, 
and the at least one member of the transforming growth 
factor-beta (TGF-~) superfamily comprises a bone morpho-
genetic protein (BMP). In such embodiments, a method for 
affecting an anatomical structure can further comprise 
regenerating at least a portion of the bone of a subject, 
wherein the bone morphogenetic protein is present in an 
initial concentration of less than about 100 micrograms per 
kilogram of body weight of the subject. Methods for affect-
ing an anatomical structure can also comprise using an 
active agent that comprises a plurality of mesenchymal 
progenitor cells. 
10 point; #-significantly different than the previous time point 
for same cell type). 
FIGS. 9A-B graphically depict the alkaline phosphatase 
activity of cell lysates on (A) tissues culture plates and (B) 
15 nanofiber meshes. (*-significantly different than the other 
cell type at same time point; #--significantly different than 
a previous time point for same cell type; $-significantly 
different than hMSC peak on plate at day 7). 
FIG. 10 graphically depicts calcium quantification depos-
20 ited by cells. (#--significantly different than growth media; 
*-significantly different than other cell type on same 
surface; $-significantly different than plate with same cell 
type). 
FIG. 11 graphically depicts calcein staining quantified by 
25 fluorescence (*-significantly greater than MSC osteogenic 
media; #-significantly greater than growth media with 
same cell type). 
Yet another aspect of the present invention includes a kit 
for affecting an anatomical structure, comprising: a mem-
brane configured to substantially conform to an anatomical 30 
structure; and a flowable hydrogel system comprising at 
least one active agent. More specifically, the membrane can 
FIG. 12 is a schematic of the cell infiltration model. 
FIGS. 13A-B illustrate the kinetics of cell infiltration on 
uncoated random nanofiber meshes. (* indicates signifi-
cantly greater than cell number on day 0. # indicates 
significantly greater than cell number on days 3 and 4. 
be a nanofiber mesh having an average pore size of less than 
about 100 micrometers, and the nano fiber mesh can further 
comprise a plurality of macropores. In an exemplary 35 
embodiment of the present invention, the kit is used to affect 
Significance was set at p<0.05). 
FIG. 14 graphically depicts the effect of coating and fiber 
alignment on cell infiltration at 48 hours after strip removal. 
(** indicates significantly greater than collagen with same 
fiber orientation. $ indicates greater than random orientation 
with same coating. Significance was set at p<0.05). 
a bone, the flowable hydrogel comprises alginate or a 
derivative thereof, and the active agent comprises a bone 
morphogenetic protein, a plurality of mesenchymal progeni-
tor cells, or combinations thereof. 
Other aspects and features of embodiments of the present 
invention will become apparent to those of ordinary skill in 
the art, upon reviewing the following description of specific, 
exemplary embodiments of the present invention in con-
junction with the accompanying figures. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. lA is a representative scanning electron microscope 
(SEM) image of a nanofiber mesh at 10,000x magnification. 
FIG. lB is a histogram of nanofiber diameter of a repre-
sentative nanofiber mesh. 
FIG. 2A provides SEM images of random and aligned 
nanofiber meshes at 2000x magnification. 
FIGS. 15A-B demonstrate the role of cell proliferation in 
40 the cell infiltration model. (* indicates significantly greater 
than random uncoated with same MMC condition (p<0.05). 
$ indicates significantly greater than random GFOGER with 
same MMC condition (p<0.05)). 
FIG. 16 graphically depicts the early effect of GFOGER 
45 coating on hMSC number. (* indicates significantly greater 
than uncoated in the same group). 
FIGS. 17 A-C demonstrate the effect of coating and fiber 
alignment on cell number and osteogenic differentiation of 
hMSCs in osteogenic media through (A) DNA amount, (B) 
50 alkaline phosphatase (ALP) activity, and (C) calcium depo-
sition. 
FIG. 18 is radiographs of femurs implanted with nanofi-
ber mesh tubes at 4 and 12 weeks. 
FIG. 2B graphically depicts fiber angle measurements of 55 
nanofiber meshes. 
FIG. 19A illustrates regenerated bone volume from µCT 
analysis FIG. 19B demonstrates failure strength derived 
from the maximum torque in torsional testing. 
FIG. 3 is a perspective view of one embodiment of a 
system for affecting an anatomical structure, such as a long 
bone. 
FIG. 4 is a cross section of one embodiment of a system 
for affecting an anatomical structure, such as a long bone. 
FIG. 5 is a perspective view of one embodiment of a 
system for affecting an anatomical structure having mac-
ropores. 
FIG. 6 illustrates the infiltration of cells and angiogenesis 
promoted by one embodiment of a system for affecting an 
anatomical structure having macropores. 
FIG. 19C illustrates cross sections of µCT images of 
regenerated bone. 
FIG. 20 shows histological analysis of newly formed bone 
60 with hematoxylin and eosin staining at 12 weeks. The defect 
in both groups contains a combination of newly formed bone 
(nb ), fibrous tissue (ft) and marrow (m). Scale bars are 200 
µm. 
FIG. 21A is a SEM image of an electrospun nanofiber 
65 mesh. 
FIG. 21B illustrates a hollow tubular implant without 
perforations made from nanofiber meshes. 
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FIG. 21C illustrates hollow tubular implant with perfo-
rations made from nanofiber meshes. 
FIG. 21D illustrates implants in segmental bone defect. 
FIG. 21E displays a photograph of the defect in a subject 
following placement of a perforated mesh tube. 
FIG. 21F displays a photograph of the defect in a subject 
after a one week incubation with the nanofiber mesh tube. 
FIG. 21G graphically depicts alginate release kinetics 
over 21 days in vitro. 
6 
humans. Mammals include, but are not limited to, humans, 
primates, horses, cows, sheep, pigs, goats, dogs, cats, rab-
bits, guinea pigs, rats, and mice. 
As used herein, the term "anatomical structure" can refer 
to many anatomical structures of animals or plants. Accord-
ingly, an anatomical structure of an animal can include, but 
is not limited to, bone, cartilage, tendons, ligaments, muscle, 
tumors, nerve, skin, organs, and tissues. In an exemplary 
FIG. 22 provides representative radiographs at 4 and 12 10 
weeks. 
embodiment of the present invention, an anatomical struc-
ture is bone, such as short bones, flat bones, and long bones. 
The term "anatomical structure" also encompasses defects, 
FIG. 23A illustrates µCT images of bone regeneration at 
4 and 12 weeks. 
FIG. 23B graphically depicts quantification of regener-
ated bone volume. 
FIG. 23C graphically depicts mean density ofregenerated 
bone. 
FIGS. 24A-B demonstrate the mechanical properties, (A) 
maximum torque and (B) torsional stiffness, offemora at 12 
weeks. 
FIGS. 25A-B provide a histological analysis at 12 weeks 
(A) 4x magnification, (B) !Ox magnification. White arrows 
point to osteocytes embedded in lacunae. Black arrows point 
to osteoblasts lining the bone surface. Scale bar is 100 µm. 
FIG. 26 illustrates vascular ingrowth at a defect site at 3 
weeks. Scale bar is 1 mm and applies to all images. "Peri" 
refers to periphery of defect. 
FIG. 27 displays representative radiographs at 2, 4 and 12 
weeks. 
FIG. 28 illustrates three-dimensional in vivo µCT images 
at 4 and 12 weeks. 
FIGS. 29A-B demonstrate quantitative µCT analysis of 
new bone volume. (* indicates significantly different 
(p<0.05)). 
FIGS. 30A-B demonstrate mean density (A) and connec-
tivity density (B) of the newly formed bone, obtained from 
µCT analysis. (* indicates significantly different (p<0.05)). 
FIG. 31 illustrates the biomechanical properties ofregen-
erated femurs at 12 weeks. (* indicates significantly different 
(p<0.05)). 
DETAILED DESCRIPTION OF THE 
INVENTION 
injuries, trauma, lesions, and the like that are associated with 
an anatomical structure. 
As used herein, the phrase "to affect an anatomical 
15 structure" refers to acting on or producing an effect or a 
change in the structure or function of an anatomical struc-
ture. Therefore, "to affect an anatomical structure" refers to 
a difference in degree from a first state, such as an untreated 
state in a subject, to a second state, such as a treated state in 
20 a subject. Consequently, the various embodiments of the 
systems and methods of the present invention can function 
to alter one or more various anatomical, physiological, and 
pathological properties of an anatomical structure. The 
alteration of one or more various anatomical, physiological, 
25 and pathological properties of an anatomical structure can 
include, but are not limited to, promoting or inhibiting 
cellular infiltration, promoting or inhibiting cellular prolif-
eration, promoting or inhibiting cellular differentiation, pro-
moting or inhibiting cellular survival, promoting or inhib-
30 iting angiogenesis, promoting or inhibiting an immune 
response, or promoting or inhibiting matrix synthesis or 
organization, among others. The alteration of one or more 
anatomical property, physiological property, pathological 
property, or various combinations thereof will depend upon 
35 the desired therapeutic effect. For example, in the context of 
a long bone defect resulting from a trauma, alteration of one 
or more anatomical, physiological, or pathological proper-
ties can include promotion of cellular proliferation, infiltra-
tion, and differentiation as well as promotion of angiogen-
40 esis in the defect site. Alternatively, in the context of 
craniosynostosis, alteration of one or more anatomical, 
physiological, or pathological properties can include inhi-
bition of cellular proliferation, infiltration, and differentia-
tion or inhibition of angiogenesis into the defect site. In yet 
45 another example, in the context of a malignant tumor, 
alteration of one or more anatomical, physiological, or 
pathological properties can include inhibition of cellular 
proliferation or survival, inhibition of angiogenesis, or 
Referring now to the figures, wherein like reference 
numerals represent like parts throughout the several views, 
exemplary embodiments of the present invention will be 
described in detail. Throughout this description, various 
components can be identified as having specific values or 
parameters, however, these items are provided as exemplary 50 
embodiments. Indeed, the exemplary embodiments do not 
limit the various aspects and concepts of the present inven-
tion as many comparable parameters, sizes, ranges, and/or 
values can be implemented. The terms "first," "second," and 
the like, "primary," "secondary," and the like, do not denote 
any order, quantity, or importance, but rather are used to 
distinguish one element from another. Further, the terms "a," 
"an," and "the" do not denote a limitation of quantity, but 
rather denote the presence of"at least one" of the referenced 
stimulation of an immune response. 
In one embodiment of the present invention, a system for 
affecting an anatomical structure comprises: a nanofiber 
mesh configured to substantially conform to an anatomical 
structure or defect region; and an active agent. A nanofiber 
mesh 100 can comprise a plurality of nanofibers 105, as 
55 shown in FIG. 1. As used herein, the term "plurality" means 
more than one. The nanofiber mesh 100 is a porous, sub-
stantially flattened structure composed of a plurality of 
interconnected nanofibers 105, as shown in FIG. lA. In 
another embodiment of the present invention, the nano fiber 
item. 
The various embodiments of the present invention pro-
vide systems and methods to affect anatomical structures of 
60 mesh 100 is plurality of interconnected microfibers (i.e., 
fibers having an average longest cross-sectional dimension 
greater than about 1000 nm). In yet another embodiment of 
the present invention, the nanofiber mesh 100 can comprise 
a one or more of nanofibers and one or more macrofibers. 
a subject. As used herein, the term "subject" refers to 
animals and plants, as well as cells and tissues derived 
therefrom. For example, the systems and methods of the 65 
present invention are applicable to a broad range of verte-
brate animals, preferably mannnals, and more preferably 
A nanofiber 105 comprises many classes of materials that 
are continuous, flexible, filaments or are in discrete elon-
gated pieces, similar to lengths of thread. As used herein, a 
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"nanofiber" means a continuous, flexible, filamentous mate-
rial having a relatively high aspect ratio (i.e., ratio of length 
to average longest cross-section). In an embodiment of the 
present invention, an aspect ratio can be at least about 5:1. 
In an embodiment of the present invention, an aspect ratio 
can be at least about 10: 1, at least about 100: 1, or at least 
about 1000: 1. 
A nanofiber 105 can have many cross-sectional shapes, 
including, but not limited to, a rectangular shape, a circular 
shape, a semicircular shape, a square shape, a pentagonal 
shape, a triangular shape, a hexagonal shape, an octagonal 
shape, a star-shape, a starburst shape, a "U" shape, a lobed 
shape, a multi-lobed shape, an arbitrary shape, or combina-
tions thereof or therebetween. In an exemplary embodiment 
of the present invention, a nanofiber 105 has a circular 
cross-sectional shape; however, one of ordinary skill in the 
art would realize that the cross-sectional shape of the 
nanofiber 105 can be varied to impart additional properties 
to the nanofiber 105 or nanofiber mesh 100, such as 
increased surface area. 
8 
tion, the nanofibers 105 are made of poly (E-caprolactone). 
In an exemplary embodiment of the present invention, the 
nanofibers 105 are made of poly (L, DL lactide). 
According to one embodiment of the present inventions, 
the nanofiber mesh 100 is produced by electrospinning 
Electrospinning has recently emerged as a technique to 
produce polymeric scaffolds for tissue engineering, with 
fiber diameters ranging from tens of nanometers to as large 
as 10 micrometers. The nanofiber mesh obtained by this 
10 process is a unique scaffold membrane that possesses struc-
tural features with a size scale similar to extracellular matrix 
(ECM) components, high porosity and large surface area to 
volume ratios. These properties allow for enhanced cellular 
attachment and spreading. Therefore, nanofiber meshes 
15 serve as an effective delivery vehicle for cells to a defect site 
Ill VIVO. 
The nanofiber mesh 100 may have a network of ran-
domly-oriented nanofibers 105 or may have a network of 
substantially aligned nanofibers 105, as shown in FIGS. 
20 2A-B. A substantially aligned nanofiber mesh 100 has a 
majority of nanofibers 105 oriented in the same direction. 
Stated another way, a substantially aligned nanofiber mesh 
100 comprises a plurality of nanofibers 105, where more 
One of ordinary skill in the art would also realize that the 
cross-sectional shape of the nanofiber 105 will determine the 
average longest cross-sectional dimension of the nanofiber 
105. For example, the average longest cross-sectional 
dimension of a nanofiber 105 having a circular cross- 25 
sectional shape will be the diameter of the nanofiber 105. In 
than about 85% of the nanofibers are aligned substantially 
parallel to an arbitrary line (i.e., within -45° and +45° of the 
arbitrary line). Conversely, a randomly-oriented nanofiber 
an alternative example, the average longest cross-sectional 
dimension of a nanofiber 105 having a rectangular cross-
sectional shape will be the length (with the proviso that the 
so-called length is greater than the so-called width) of the 30 
rectangular cross-section of the nanofiber 105. In yet another 
example, the average longest cross-sectional dimension of a 
nanofiber 105 having a starburst cross-sectional shape will 
mesh 100 comprises a plurality of nanofibers 105, where less 
than about 85% of the nanofibers are aligned substantially 
parallel to an arbitrary line. In an exemplary embodiment of 
the present invention, a randomly-oriented nanofiber mesh 
100 comprises a plurality ofnanofibers 105, where less than 
about 55% of the nanofibers are aligned substantially par-
allel to an arbitrary line. 
be the distance between the two furthest points of the 
starburst cross-section of the nanofiber 105. 
In an embodiment of the present invention, a nanofiber 
105 has an average longest cross-sectional dimension rang-
ing from about 10 nm to about 1000 nm. In another 
embodiment of the present invention, a nanofiber 105 has an 
average longest cross-sectional dimension ranging from 
about 50 nm to about 600 nm. In yet another embodiment of 
the present invention, a nano fiber 105 has an average longest 
cross-sectional dimension ranging from about 50 nm to 
about 300 nm. In yet another embodiment of the present 
invention, a nanofiber 105 has an average longest cross-
sectional dimension ranging from about 50 nm to about 300 
nm (FIG. lB). In still another embodiment of the present 
invention, a nanofiber 105 has an average longest cross-
sectional dimension ranging from about 50 nm to about 150 
nm. In an exemplary embodiment of the present invention, 
a nanofiber 105 has an average longest cross-sectional 
dimension of about 150 nm. 
The nanofibers 105 of the present invention can be made 
of many biocompatible materials, including degradable 
materials, non-degradable materials, or combinations 
thereof. Examples of such materials include but are not 
limited to, polytetrafluoroethylenes, perfluorinated poly-
mers, polypropylenes (e.g., polypropylene fumarate), poly-
ethylenes (e.g., polyethylene glycol), polyethylene teraptha-
lates, silicones, silicone rubber, polysulfones, polyurethanes, 
polycarboxylates, polycarbonates, polyketals, polyesters 
(e.g., poly lactic acid and polyglycolic acid), polyorthoesters, 
polyacrylics, polyhydroxymethacrylates, polymethylmeth-
acrylates, polyamides, polycaprolactones, polyanhydrides, 
collagen, agarose, alginate, gelatin, fibrinogen, silk, chito-
san, hyaluronic acid, co-polymers thereof, and combinations 
thereof. In one exemplary embodiment of the present inven-
The nanofiber mesh 100 is a porous, substantially flat-
35 tened structure composed of a plurality of interconnected 
nanofibers 105, as shown in FIG. lA. The nanofiber mesh 
100 can have an average thickness ranging from about 50 
nm to about 10 mm. In an exemplary embodiment of the 
present invention, the nanofiber mesh 100 has an average 
40 thickness ranging from about 100 nm to about 1 mm. In 
another exemplary embodiment, the nanofiber mesh 100 has 
an average thickness ranging from about 300 µm to about 
400 µm. 
The plurality of interconnected nanofibers 105 creates a 
45 network or mesh of fibers, which confers the nanofiber mesh 
100 with plurality of pores 110 (FIG. lA). These pores 110 
may have varying characteristics, such as size, shape, and 
tortuosity. Preferably, the pores 110 are constructed such that 
they pass directly through the nanofiber mesh 100. In one 
50 embodiment of the present invention, the pores 110 have an 
average longest cross-sectional dimension ofless than about 
100 µm. In another embodiment of the present invention, the 
pores 110 have an average longest cross-sectional dimension 
of less than about 10 µm. In another embodiment of the 
55 present invention, the pores 110 have an average longest 
cross-sectional dimension of less than about 5 µm. In yet 
another embodiment of the present invention, the pores 110 
have an average longest cross-sectional dimension of less 
than about 2 µm. In yet another embodiment of the present 
60 invention, the pores 110 have an average longest cross-
sectional dimension of about 1 µm. 
The nanofiber mesh 100 is a substantially flattened struc-
ture, composed of a network of biocompatible nanofibers 
105, that can be configured to substantially conform to an 
65 anatomical structure. Configuring the nanofiber mesh 100 to 
substantially conform to an anatomical structure may take 
place during construction of the mesh. Alternatively, the 
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nanofiber mesh 100 may be configured after construction, 
for example during implantation. In yet another alternative, 
the nanofiber mesh 100 may be configured during construc-
tion and further configured after construction. 
10 
transforming growth factor-beta (TGF-~) superfamily. 
Members of the TGF-~ superfamily, include but are not 
limited to, TGF-~ (e.g., TGF-~1, TGF-~2, TGF-~3) bone 
morphogenetic protein (BMP) (e.g., BMP2, BMP3, BMP4, 
BMP5, BMP6, BMP7, BMP8a, BMP8b, BMPlO, BMPll, 
BMP12, BMP13, BMP14, BMP15), inhibin (e.g., InhibinA, 
Inhibin B), activin (e.g., ActivinA, Activin B, ActivinAB), 
growth differentiation factor (GDF!, GDF2, GDF3, 
GDF3A, GDF5, GDF6, GDF7, GDFS, GDF9, GDFlO, 
When implanted, the nanofiber mesh 100 can be config-
ured to define a fillable space. Therefore, the implanted 
nanofiber mesh 100 provides a porous permeable membrane 
between the established fillable space of the anatomical 
structure and the milieu surrounding the anatomical struc-
ture. As used herein, the phrase "substantially conform to an 
anatomical structure" refers to situations where the nanofi-
ber mesh 100 may delineate the entire boundary of the 
space, or alternatively, the nanofiber mesh 100 may delin-
eate only a portion of the space and the remainder of the 
boundary being delineated by the anatomical structure or 
adjacent structures or tissues of the subject. The parameters 
and configuration of the fillable space established by implan-
tation of the nanofiber mesh 100 is approximately equivalent 
to the anatomical structure or defect associated therewith 
10 GDFll, GDF15), Nodal, Lefty (e.g., Lefty 1, Lefty2), and 
anti-Mullerian hormone (sometimes referred to as Mullerian 
Inhibiting Substance), among others. More specifically, the 
active agent can be recombinant human BMP2 (rhBMP2) or 
recombinant human BMP7 (rhBMP7), or combinations 
15 thereof. In another exemplary embodiment of the present 
invention, the active agent 320 may comprise a growth 
factor, such as insulin-like growth factor 1 (IGF-1), vascular 
endothelial growth factor (VEGF), platelet-derived growth 
that is desired for treatment with the systems and methods of 20 
the present invention. 
factor (PDGF), or fibroblast growth factor (FGF). 
In another exemplary embodiment, the active agent 320 
can comprise a cell or a plurality of cells, such as a 
mesenchymal progenitor cell, which can be derived from 
amniotic fluid, bone marrow, adipose tissue, and the like. 
Bone marrow derived mesenchymal stem cells (MSCs) have 
FIG. 3 illustrates one example of a system 300 for 
affecting an anatomical structure, such as bone 305. The 
system comprises a nanofiber mesh 100 is configured to 
substantially conform to an anatomical structure, in this case 
a long bone 305. The nanofiber mesh 100 is configured to 
define a fillable space 310. In this case, the nanofiber mesh 
100 is wrapped around the bone defect to establish a fillable 
space 310 for bone growth. 
25 demonstrated a strong potential for differentiation into bone 
forming cells and have been shown to promote repair of 
critically-sized bone defects in pre-clinical animal studies. 
Other cells that may be suitable for applications related to 
regeneration and remodeling of bone include, but are not 
30 limited to, osteoblasts, osteoclasts, osteocytes, and bone-
lining cells 
Various embodiments of the systems and methods for 
affecting an anatomical structure include an active agent 
320. As used herein, the term "active agent" can include, 
without limitation, agents for gene therapy, analgesics, anti-
arthritics, anti-asthmatic agents, anti-cholinergics, anti-con-
vulsants, anti-depressants, anti-diabetic agents, anti-diarrhe-
als, anesthetics, antibiotics, antigens, anti-histamines, anti-
infectives, anti-inflammatory agents, antimicrobial agents, 
anti-migraine preparations, anti-nauseants, anti-neoplastics, 
anti-parkinsonism drugs, anti-pruritics, anti-psychotics, 
anti-pyretics, anti-spasmodics, anorexics, anti-helminthics, 40 
antiviral agents, nucleic acids, DNA, RNA, polynucleotides, 
nucleosides, nucleotides, amino acids, peptides, proteins, 
carbohydrates, lectins, lipids, fats, fatty acids, viruses, anti-
gens, immunogens, antibodies and fragments thereof, sera, 
cytokines, chemokines, immune stimulants, immune sup- 45 
pressors, sympathomimetics, xanthine derivatives, cardio-
vascular agents, potassium channel blockers, calcium chan-
nel blockers, beta-blockers, alpha-blockers, anti-
arrhythmics, anti-hypertensives, diuretics, anti-diuretics, 
vasodilators comprising general, coronary, peripheral, or 50 
cerebral, central nervous system stimulants, vasoconstric-
tors, gases, growth factors, growth inhibitors, hormones, 
estradiol, steroids, progesterone and derivatives thereof, 
testosterone and derivatives thereof, corticosteroids, angio-
genic agents, anti-angiogenic agents, hypnotics, muscle 55 
relaxants, parasympatholytics, psychostimulants, sedatives, 
tranquilizers, ionized and non-ionized active agents, anti-
fungal agents, metals, small molecules, pharmaceuticals, 
hemotherapeutic agents, wound healing agents, indicators of 
change in the bio-environment, enzymes, nutrients, vita- 60 
mins, minerals, coagulation factors, neurochemicals, cellu-
lar receptors, radioactive materials, cells, chemical or bio-
logical materials or compounds that induce a desired 
biological or pharmacological effect, and combinations 
thereof. 
In an exemplary embodiment of the present invention, the 
active agent 320 comprises at least one member of the 
In one embodiment of the present invention, the nanofiber 
mesh 100 can be functionalized or surface-modified with 
one or more active agents. For example, the nanofiber mesh 
35 100 can be functionalized or surface-modified with an 
osteogenic biomolecule. As used herein, the term "biomol-
ecule" refers many organic molecules that are produced by 
a living organism, including large polymeric molecules such 
as proteins, polysaccharides, and polynucleotides, including 
smaller peptides, oligosaccharides, and nucleic acids, as 
well as small molecules such as primary metabolites, sec-
ondary metabolites, and other biological products. In one 
exemplary embodiment, the nanofiber mesh can be func-
tionalized or surface-modified to mimic the extracellular 
matrix. For example, the osteogenic biomolecule can 
include proteoglycans, proteins, peptides, polysaccharides, 
and components thereof, among others. As used herein, 
"mimicking the extracellular matrix" refers to biomolecules 
(e.g., proteoglycans, proteins, peptides, polysaccharides, 
and components thereof) having structural identity to a 
component of the extracellular matrix or sufficient structural 
homology to a component of the extracellular matrix, 
thereby effectively replicating the same interactions associ-
ated with that component of the extracellular matrix. These 
biomolecules can include, but are not limited to, gly-
cosaminoglycans (e.g., chondroitin sulfate, heparin sulfate, 
keratin sulfate, hyaluronic acid), or proteins (e.g., collagen, 
elastin, fibronectin, laminin) or peptides derived from these 
proteins (e.g., glycine-pheny lalanine-hydroxyproline-gly-
cine-glutamate-arginine (GFOGER) domain from residues 
502-507 of the a 1 (I) chain of type I collagen), among others. 
The system for affecting an anatomical structure can 
further comprise a carrier substance 315. As used herein, the 
term "carrier substance" can comprise many media, includ-
65 ing but not limited to, a fluid, liquid, solid, solution, sus-
pension, emulsion, gas, vapor, gel, dispersion, a flowable 
material, a multiphase material, or combination thereof. In 
US 9,452,049 B2 
11 12 
retains the active agent 320 at the defect site, which permits 
sustained delivery of the active agent 320, thereby promot-
ing the infiltration and proliferation of osteoprogenitor cells. 
The nanofiber mesh 100, in turn, provides a substrate to 
facilitate the migration and proliferation of progenitor cells 
on the periosteal surface. The porosity of the nanofiber mesh 
100 permits sufficient retention of the active agent 320 at the 
defect site, while allowing for the release of the active agent 
320 (through diffusion or hydrogel degradation), which 
establishes a gradient to attract osteoprogenitor cells to the 
defect site. In addition, it is believed that the porosity of the 
nano fiber mesh 100 permits the infiltration of nutrients to the 
defect site. 
an exemplary embodiment of the present invention, the 
carrier substance comprises a flowable polymer. The flow-
able polymer can comprise many suitable hydrophilic, 
hydrophobic, and amphiphilic polymers known in the art. In 
some embodiments of the present invention, the flowable 
polymer can comprise a hydrophilic polymer, including, but 
not limited to, acrylates, acrylamides, acetates, acrylic acids, 
vinyl alcohols, glycols, polysaccharides, co-polymers 
thereof, or combinations thereof. In various embodiments of 
the present invention, the polymer can have many topologies 10 
including, but not limited to, a branched topology, a graft 
topology, a comb topology, a star topology, a cyclic topol-
ogy, a network topology, or combinations thereof, among 
others. The crosslinker of the polymer particles can be many 
suitable crosslinkers known in the art including, but not 
limited to, N,N', methylenebis(acrylamide), poly(ethylene 
glycol) (PEG) diacrylate, N,N'-dihydroxyethylene-bisacryl-
amide, N,0-(dimethacryloyl)hydroxylamine, ethylene gly-
col dimethacrylate, divinylbenzene, divalent cations (e.g., 
Ca2+ and Mg2 +), or combinations thereof. In an exemplary 20 
embodiment of the present invention, the carrier substance 
comprises an alginate or a derivative thereof. Such deriva-
tives are described in U.S. Pat. No. 6,642,363, which is 
incorporated by reference in its entirety. An example of an 
alginate derivative is alginate modified with a G4 RGDASSP 25 
peptide sequence. 
In various embodiments of the present invention, the 
15 nanofiber mesh can be attached to the anatomical structure 
Accordingly, an embodiment of the present invention 
comprises a method for affecting an anatomical structure, 
which involves adapting a nanofiber mesh 100 to an ana-
tomical structure of a subject so that the nanofiber mesh 30 
substantially conforms to the anatomical structure, and at 
least a portion of the nanofiber mesh 100 defines a fillable 
space 310 followed by flowing a carrier substance 315 into 
the fillable space 310. Thus, the flowable carrier substance 
315 is capable of substantially filling the fillable space 310. 35 
In the context of regeneration of bone in a bone defect, the 
flowable aspect of the carrier substance provides a signifi-
cant advancement over prior art methods, which utilize 
pre-formed gels. According to the systems and methods of 
the present invention, a flowable carrier substance 315 (e.g., 40 
an injectable hydrogel system) permits complete or near 
complete filling of the space 310 created by the nanofiber 
mesh 100. As shown in FIG. 3, the fillable space 310 can be 
filled with a carrier substance 315, such as a hydrogel, 
comprising an active agent 320. Thus, the use of a flowable 45 
hydrogel system may be readily adapted for use in not only 
nanofiber meshes, microfiber meshes, and combinations 
thereof, but can also be used with membranes (i.e., polymer 
films, which can be made of many the degradable materials, 
non-degradable materials, or combinations thereof, 50 
described above). 
In one exemplary embodiment of the present invention, 
the carrier substance 315 can contain the active agent 320. 
In an exemplary embodiment of the present invention, the 
carrier substance comprises alginate or a derivative thereof, 55 
and the active agent comprises a member of the TGF-~ 
superfamily, such as a bone morphogenetic protein (BMP). 
Although not wishing to be bound by any particular 
theory, it is believed that the nanofiber mesh and flowable 
hydrogel carrier operate synergistically to promote new 60 
bone growth. In methods for repairing a bone defect, the 
nanofiber mesh 100 is positioned on the periosteal surface to 
define a space 310, as shown in FIG. 4. The flowable 
hydrogel carrier 315, which contains the active agent 320, 
operates to effectively fill the defect space 310 defined by the 65 
at least a portion of the nanofiber mesh 100 and the bone 
305. Upon polymerization, the polymerized hydrogel 315 
with the use of various biocompatible fastening elements, 
such as sutures, staples, tacks, screws, adhesives, or other 
fastening elements known in the art of fixing articles to 
anatomical structures. Alternatively, the nano fiber mesh may 
simply be surgically placed on the anatomical structure 
without using an attachment element. 
In an attempt to further facilitate the infiltration of cells 
osteoprogenitor cells and the invasion of vasculature to the 
defect site, the nanofiber mesh 100 can be modified to 
comprise a plurality of macropores 505, as shown in FIG. 5. 
These macropores 505 can have an average longest cross-
section dimension ranging from about 100 µm to about 2000 
µm. In an exemplary embodiment of the present invention, 
the macropores 505 can have an average longest cross-
section dimension of about 1 mm, and these macropores can 
be spaced approximately 1.5 mm apart. Although not wish-
ing to be bound by any particular theory, it is believed that 
the macropores 505 facilitate the invasion of vasculature 605 
and the migration of cells 610 into the defect site, such as 
osteoprogenitor cells. (FIG. 6). In modifying a nanofiber 
mesh 100 to include macropores 505 that facilitate the 
infiltration of cells osteoprogenitor cells and the invasion of 
vasculature to the defect site, design considerations include, 
but are not limited to, the number of macropores 505, the 
average longest cross-sectional dimension of the macropore 
505, the distribution of macropores 505 on the nanofiber 
mesh 100, and the shape of the macropores 505. 
One of skill in the art would realize that the composition 
and viscosity of the carrier substance 315 may be varied 
depending upon the composition and design of the nanofiber 
mesh 100 as well as the composition of the active agent 320. 
Thus, the carrier substance 315 can further comprise various 
thickening agents, diluents, and suspending agents to facili-
tate suspension, retention, and controlled diffusion of the 
active agent in the carrier substance. For example, active 
agents may be suspended in a carrier substance that dem-
onstrates reduced viscosity through the use of nanoparticles 
or microtubes. 
Thus, the systems and methods of the present invention 
contemplate a method for treating a bone defect, comprising 
adapting a nanofiber mesh to a bone defect of a subject so 
that the nanofiber mesh substantially conforms to the bone 
defect, and at least a portion of the nano fiber mesh defines 
a fillable space; and flowing a carrier substance into the 
fillable space, the carrier substance comprising a therapeu-
tically effective amount of an active agent. 
The phrase "therapeutically effective amount" or "effec-
tive amount" as used herein is an amount of a compound that 
produces a desired therapeutic effect in a subject, such as 
inducing bone regeneration. The precise therapeutically 
effective amount is an amount of the composition that will 
yield effective results in terms of efficacy of treatment in a 
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given subject. This amount (i.e., dosage) may vary depend-
ing upon a number of factors, including, but not limited to, 
the characteristics of the active agent (including activity, 
pharmacokinetics, pharmacodynamics, and bioavailability), 
the physiological condition of the subject (including age, 
sex, disease stage, general physical condition, and respon-
siveness to a given dosage), the nature of the carrier sub-
stance, and the composition of the nanofiber mesh. One 
skilled in the clinical and pharmacological arts will be able 
to determine a therapeutically effective amount through 10 
routine experimentation, namely by monitoring a subject's 
response to administration of a compound and adjusting the 
dosage accordingly. 
In an exemplary embodiment of the present invention, a 
method of treating a bone defect comprises administering a 15 
therapeutically effective dose of at least one TGF-~ member 
of the TGF-~ superfamily, such as a bone morphogenetic 
protein (e.g., rhBMP-2, rhBMP-7). In one embodiment, a 
therapeutically effective amount of bone morphogenetic 
protein is less than about 100 micrograms per kilogram of 20 
body weight of the subject. In another embodiment, a 
therapeutically effective amount of bone morphogenetic 
protein is less than about 50 micrograms per kilogram of 
body weight of the subject. In yet another embodiment, a 
therapeutically effective amount of bone morphogenetic 25 
protein is less than about 25 micrograms per kilogram of 
body weight of the subject. In still another embodiment, a 
therapeutically effective amount of bone morphogenetic 
protein is about 20 micrograms per kilogram of body weight 
of the subject. 30 
All patents, patent applications, and references included 
herein are specifically incorporated by reference in their 
entireties. 
It should be understood, of course, that the foregoing 
relates only to exemplary embodiments of the present inven- 35 
tion and that numerous modifications or alterations may be 
made therein without departing from the spirit and the scope 
of the invention as set forth in this disclosure. Therefore, 
while embodiments of this invention have been described in 
14 
tigated the effects of modulating nanofiber bioactivity and 
orientation on stem cell progranmiing. Our results indicate 
that functionalization of nanofiber meshes with a collagen-
mimetic peptide enhanced the migration, proliferation and 
osteogenic differentiation of cells. Fiber alignment improved 
cell migration along the direction of fiber orientation. 
Finally, a nanofiber mesh based hybrid system for growth 
factor delivery was developed for bone repair and tested in 
a challenging animal model. The delivery of bone morpho-
genetic protein (BMP) via this system resulted in the func-
tional restoration of limb function, and in fact proved more 
efficacious than the current clinical standard for BMP deliv-
ery. 
The studies performed in this thesis have suggested novel 
techniques for improving the repair of clinically challenging 
bone defects. They indicate that delivery of BMP via the 
hybrid system may reduce the dose and side effects of BMP, 
thereby broadening the use of BMP based bone augmenta-
tion procedures. Therefore, this nanofiber mesh based sys-
tem has the potential to become the standard of care for 
clinically challenging bone defects, including large bone 
defects, open tibial fractures, and nonunions. 
Example 1 
Colonization and Osteogenic Differentiation of 
Different Stem Cell Sources on Electrospun 
Nanofiber Meshes 
The purpose of this Example was to investigate the 
attachment, colonization and osteogenic differentiation of 
human MSCs (hMSCs) and human AFS (hAFS) cells on 
electrospun nanofiber meshes. This Example demonstrates 
that electrospun meshes are able to robustly support these 
functions for both cell types. Compared to tissue culture 
plastic, there is delayed initial attachment and proliferation, 
but enhanced mineralization at a later time point. Differ-
ences in the kinetics of osteogenic differentiation were 
observed between hMSCs and hAFS cells. Cell-seeded 
detail with particular reference to exemplary embodiments, 40 nanofiber meshes were also effective in colonizing three 
those skilled in the art will understand that variations and dimensional scaffolds in an in vitro model. These results 
modifications can be effected within the scope of the inven-
tion as defined in the appended claims. Accordingly, the 
scope of the various embodiments of the present invention 
should not be limited to the above discussed embodiments, 45 
and should only be defined by the following claims and all 
equivalents. 
The present invention is further illustrated by way of the 
examples contained herein, which are provided for clarity of 
understanding. The exemplary embodiments should not to 50 
be construed in any way as imposing limitations upon the 
scope thereof. On the contrary, it is to be clearly understood 
that resort may be had to various other embodiments, 
modifications, and equivalents thereof which, after reading 
the description herein, may suggest themselves to those 55 
skilled in the art without departing from the spirit of the 
present invention or the scope of the appended claims. 
EXAMPLES 
provide support for the use of the nanofiber mesh as a cell 
delivery vehicle for the repair of bone defects in vivo. 
Materials and Methods 
Fabrication of nanofiber meshes. A polymer solution was 
made by dissolving 13% (w/v) poly (E-caprolactone) (PCL) 
(Sigma-Aldrich, St. Louis, Mo.) in a 40:60 volume ratio of 
dichloromethane (DCM):dimethylformamide (DMF) 
(Sigma-Aldrich). PCL pellets were added to the solvent 
mixture, and gently stirred for 16-24 hours. The polymer 
solution was loaded in a 3 mL syringe (Becton-Dickinson, 
Franklin Lakes, N.J.), and a 22 gauge blunt stainless steel 
needle (Jensen Global Inc., Santa Barbara, Calif.) was 
attached to the syringe end. The syringe was mounted on a 
syringe pump (Harvard Apparatus, Holliston, Mass.), and 
the pump was set to infuse at a rate of0.75 mL/hr. A flat, 6x6 
inch copper plate (McMaster-Carr, Atlanta, Ga.) covered 
with aluminum foil was used to collect the fibers, and placed 
at a distance of 20 cm from the needle end. Fibers were 
The following examples demonstrate the use of electro-
spun nanofiber mesh scaffolds for bone regeneration. Nano-
fiber meshes were utilized in a three-pronged approach. 
First, nanofiber meshes were validated their ability to 
robustly support osteogenic cell functions, including prolif-
eration and matrix mineralization. We also demonstrated 
their efficacy as a cell delivery vehicle. Second, we inves-
60 electrospun for 50 minutes at a voltage of 14 kV, supplied by 
a high voltage power supply (Ganmia High Voltage 
Research, Ormond Beach, Fla.), to obtain a thin sheet of 
nanofiber mesh. To remove any residual solvent, the meshes 
were placed in a dessicator for at least one day before further 
65 use. 
Nanofiber mesh morphology. The morphology of the 
nanofiber meshes was examined using a Scanning Electron 
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Microscope (SEM). A small piece of the dry nanofiber mesh 
was cut and mounted on a metal stub using double-sided 
adhesive tape. A thin layer of gold was then deposited on the 
mesh sample for 80 seconds using a sputter coater (Quorum 
Technologies, East Granby, Conn.). The gold-coated sample 5 
was then viewed under a Hitachi S-800 Field Emission SEM 
(Hitachi HTA, Pleasanton, Calif.) with 10 kV accelerating 
voltage. The diameters of the fibers were quantified by 
analyzing the SEM images (at 7000x magnification) using a 
custom MATLAB® (MATLAB® 7.0 R14, The Math Works 10 
Inc., Natick, Mass.) program. A total of at least 75 distinct 
fibers were measured from four randomly chosen locations. 
16 
ethidium homodimer-1 was detected by using a 543-nm 
Helium-Neon laser and a long pass 560 filter. 
DNA content. Samples were harvested after 1, 7, 14 and 
28 days to evaluate the construct cellularity, which was 
assessed by determining the DNA content. The cells were 
first lysed by freeze-thawing the constructs three times in 
0.05% Triton X-100 (Sigma-Aldrich) with vigorous vortex-
ing. To freeze the samples, they were placed in dry ice 
cooled methanol (Sigma-Aldrich) for 5 minutes. Samples 
were then thawed in a room temperature water bath. The 
DNA amount in the lysate was quantified using the 
PicoGreen® dsDNA Quantitation Kit (Molecular Probes, 
Eugene, Oreg.), and standardized using Lambda DNA solu-
tions of known concentrations. A working solution of the 
Culture of AFS cells and MSCs. Human amniocentesis 
cultures were harvested by trypsinization, and subjected to 
c-kit immunoselection. hAFS cells were subcultured rou-
tinely at a dilution of 1 :4 to 1 :8, and not permitted to expand 
beyond 70% confluence. The hAFS cells were passaged in 
aMEM (Minimum Essential Medium Alpha) supplemented 
with 16% fetal bovine serum (ES Cell-qualified FBS), 100 
U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine 
(Invitrogen, Carlsbad, Calif.), 18% Chang Band 2% Chang 
C (Irvine Scientific, Santa Ana, Calif.). In all experiments, 
cells were used at passages 16-17. 
15 PicoGreen® reagent was made following the manufacturer's 
protocol, and incubated with experimental samples in the 
dark for 5 minutes at room temperature. The fluorescence 
was measured on a plate reader (HTS 7000, Perkins-Elmer, 
Waltham, Mass.) at an excitation of 485-nm and emission of 
Human MSCs derived from the bone marrow were 
obtained from the Tulane University Center for Gene 
Therapy (New Orleans, La.) at passage 1. Cells were iso-
lated using bone marrow aspirates from the iliac crest of 
normal adult donors. For expansion, these cells were plated 
at a density of 50 cells/cm2 , and cultured in hMSC growth 
media. The hMSC growth media consisted of aMEM (Invit-
rogen) supplemented with 16% FBS (Atlanta Biologicals, 
Atlanta, Ga.), 100 U/ml penicillin, 100 µg/ml streptomycin, 
and 2 mM L-glutamine (Invitrogen). The cells were subcul-
tured once they reached a confluency of ±70%. Passage 2-3 
hMSCs were then used for all experiments. 
20 535-nm. All samples were run in triplicate, and the DNA 
content was normalized to the culture surface area of the 
samples. 
Alkaline Phosphatase (ALP) activity. To determine the 
osteogenic differentiation of the cells on nanofiber meshes, 
25 the ALP activity assay was performed. In this assay, the 
release of p-nitrophenol from p-nitrophenyl phosphate by 
the ALP enzyme is measured. The same lysate solution that 
was used to determine DNA content was used for this 
purpose. The ALP substrate working solution was made by 
30 mixing equal parts of 20 mM p-nitrophenyl phosphate, 1.5 
M 2-Amino-2-Methyl-1-Propanol (pH 10.25) and 10 mM 
MgC12 . The experimental samples were mixed with the 
freshly made substrate working solution, and incubated for 
1 hour at 37° C. The reaction was stopped by adding IN 
35 NaOH, and the absorbance was measured at 405 nm on a 
plate reader (Power Wave XS, Biotek, Vt.). All samples were 
run in triplicate and compared to p-nitrophenol standards. 
The ALP activity was normalized by the incubation time and 
Cell culture on nanofiber fiber meshes. Square 15 mm 
samples were cut from nanofiber mesh sheets using scissors. 
Samples were placed in 24-well culture plates, submerged in 
200 proof ethanol (Sigma-Aldrich), and sterilized by allow-
ing the ethanol to evaporate overnight. After the samples had 40 
dried completely, they were pre-wetted with sterile 70% 
ethanol for 30 minutes. The 70% ethanol was then aspirated, 
and sterile dead weights were placed around the samples to 
prevent them from floating. The mesh samples were next 
rinsed three times with excess sterile PBS (Mediatech Inc., 45 
Manassas, Va.). An 800 µL volume of media was placed in 
each well containing the samples. The control groups 
received hMSC growth media, whereas the osteogenic 
groups were further supplemented with 10 nM dexametha-
sone, 6 mM ~-glycerol phosphate, 50 µg/ml ascorbic acid 50 
2-phosphate and 50 ng/ml L-thyroxine (Sigma-Aldrich). 
hMSCs and hAFS cells were then seeded onto nanofiber 
meshes in approximately 200 µL of hMSC media such that 
the density of cells was 20,000 cells/cm2 . Cells were also 
cultured in tissue culture treated 24-well plates at the same 
density for comparison. Media was changed every 3-4 days, 
and the constructs were cultured for up to 4 weeks. 
the amount of DNA obtained from the PicoGreen® assay. 
Calcium content. To quantify matrix mineralization, the 
calcium deposited by cells on nanofiber meshes after 28 
days was determined using the Arsenazo III dye. Samples 
were vortexed with 1 N acetic acid overnight to extract the 
calcium into solution. The extract was mixed with the 
Arsenazo III reagent (Diagnostic Chemicals Limited, 
Oxford, Conn.), incubated for 30 seconds at room tempera-
ture, and the absorbance read at 650 nm on a plate reader 
(PowerWave XS, Biotek). The samples were assayed in 
triplicate and compared to Calcium Chloride (CaC12 ) stan-
dards. 
Calcein staining and quantification. For visualization of 
the mineral deposited by the cells, the samples were stained 
using calcein on day 28. Briefly, a stock solution of 100 
µg/ml calcein (Sigma-Aldrich) in PBS (pH 7.4) was added 
55 to the media on top of the samples, such that the final 
concentration of calcein was 10 µg/ml. The samples were 
incubated in the calcein solution for 4 hours in the incubator. 
After rinsing twice with PBS and fixing with 10% neutral 
buffered formalin (EMD Chemicals, Gibbstown, N.J.), 
Cell viability. On days 1, 7, 14 and 28, the viability of the 
cells in the constructs was assessed using the Live/Dead® 
staining kit (Molecular Probes, Invitrogen). Harvested con-
structs were rinsed in PBS and incubated in 4 µM calcein-
AM and 4 µM ethidium homodimer-1 for 45 minutes at 
room temperature. The samples were again rinsed in PBS, 
and images were obtained on a Zeiss LSM 510 confocal 
microscope (Carl Zeiss, Thomwood, N.Y.). Green fluores-
cence of calcein-AM was detected by using a 488-nmArgon 
ion laser and a band pass 505-550 filter. Red fluorescence of 
60 samples were rinsed with excess of DI water. The fluores-
cence of the samples was read on a fluorescence plate reader 
(HTS 7000, Perkins-Elmer) at an excitation of 485-nm and 
emission of 535-nm. Following this, the same samples were 
imaged using an inverted microscope (Axio Observer.Zl, 
65 Carl Zeiss) and a FITC filter. 
Fourier Transform Infrared (FTIR) Spectroscopy. On day 
28, constructs were also harvested for analyzing the chemi-
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Live/Dead® staining kit. The live cells are stained green, 
whereas the dead cells appear red. At the same time points, 
DNA from the samples was extracted and quantified to 
estimate the number of cells on the meshes, as well as in the 
culture wells. The Live/Dead images illustrate that both cell 
types attached to the nanofiber meshes by day 1 and were 
able to spread out by day 7. During days 7-14 the number of 
cells increased considerably, and by day 28, the cells were 
confluent on the meshes. The viability of both cell types on 
cal composition of the mineral deposited on the nanofiber 
meshes. Samples were dehydrated in 100% ethanol and 
dried at 50° C. overnight. Acellular PCL nano fiber mesh was 
used as a negative control. After dehydration, the samples 
were cut into small pieces, mixed with potassium bromide 5 
(Sigma-Aldrich), and pressed into pellets using a custom 
built apparatus. Samples were analyzed with a Nicolet 
Nexus 470 FTIR spectrometer (Thermo-Nicolet, Madison, 
Mich.). Sixty four scans were acquired at 4 cm- 1 resolution 
under nitrogen purge. 10 the meshes was found to be high, as seen by the extensive 
green stain, though a few dead cells were detected. No 
differences were observed in the viability and colonization 
between the two cell types. 
Cell delivery by nanofiber mesh in vitro. The ability of a 
cell seeded nano fiber mesh to serve as a cell delivery vehicle 
was studied using an in vitro model. AFS cells were seeded 
on to nanofiber mesh samples (15x10 mm) at a density of 
200,000 cells/cm2 . The cells were allowed to attach to the 15 
mesh overnight. On the following day, each cell seeded 
mesh was wrapped around a cylindrical collagen scaffold 
(dry dimensions: 4 mm diameter and 9 mm length) asepti-
cally, such that the cells were facing the scaffold. The 
scaffolds were punched from a fibrous collagen sheet (aver- 20 
age pore size 61.7 µm, 93.7% pore volume, Kensey Nash, 
Exton, Pa.). The mesh was held in position by placing two 
interrupted silk sutures through the mesh and scaffold at the 
two ends of the scaffold. For comparison, we also seeded 
300,000 cells throughout collagen scaffolds by pipetting the 25 
cell suspension directly in the scaffolds. There was no 
nanofiber mesh in this control group. The constructs were 
statically cultured in hAFS cell growth media. After two 
weeks, the mesh was taken off, following which the mesh 
and scaffold were stained with the Live/Dead® staining kit 30 
(Molecular Probes, Invitrogen) to visualize the cell migra-
tion into the scaffold. A confocal microscope (Zeiss LSM 
510, Carl Zeiss) was used to take serial images to create 
three dimensional images. 
Data analysis. Results are presented as mean±standard 35 
error of the mean (SEM). Analysis of variance (ANOVA) 
was performed on data, with pairwise comparisons done 
using the Tukey multiple comparison procedure. A 
p-value<0.05 was considered significant. Residuals were 
used for diagnosing the appropriateness of the model by 40 
analyzing the constancy of error variance and normality of 
error terms. Wherever required, remedial measures were 
taken by transforming the data according to the Box-Cox 
procedure, or by using weighted least squares to make the 
error variance constant and the error distribution normal 45 
Minitab® 15 (Minitab Inc., State College, Pa.) was used to 
perform the statistical analysis. 
Results 
The DNA quantification over the four week culture period 
was used to compare the colonization kinetics of the two cell 
types on tissue culture plates and nanofiber meshes, respec-
tively (FIGS. SA-D). There was significant increase in DNA 
with time for both cell types, on plates as well as meshes, 
indicating cellular proliferation. On plates, the number of 
hAFS cells increased between days 1-7 but did not change 
significantly after that, suggesting rapid initial proliferation 
and confluency around day 7 (FIG. SA). On the other hand, 
hMSCs increased in numbers between both days 1-7 and 
days 14-28. However, this result is an artifact of hMSC 
culture on the plates, as the hMSCs were found to lift off the 
plate after confluence around day 7 to form a pellet, and then 
repopulate the plate. This pelleting behavior was not seen 
with the hAFS cells for up to 28 days, though the hAFS cells 
do ultimately lift off the plate. The hMSC repopulation 
explains the increase in hMSC cell number between days 
14-28 and the differences seen between hMSCs and hAFS 
cells on days 14 and 28. There were also significantly more 
hAFS cells than hMSCs on day 1, suggesting a higher initial 
attachment and/or proliferation rate. 
The pelleting phenomenon does not occur on the nano-
fiber meshes, even at a later time points. There was a 
significant increase in DNA for both cell types between days 
1-7, and an even higher increase between days 7-14, corre-
sponding to the Live/Dead images (FIG. SB). The number of 
cells did not change significantly after that, suggesting 
confluency of the cells on the nanofiber meshes. There were 
no significant differences in the DNA between hMSCs and 
hAFS cells at any time point. 
The colonization kinetics of hAFS cells on the nano fiber 
meshes was also compared with that on the tissue culture 
plates (FIGS. SC-D). On days 1, there was significantly less 
DNA on the mesh compared to plates, suggesting that not all 
cells attach to the nanofibers within the first 24 hours. The 
same trend was seen on day 7. However, by day 14, there Morphology of nanofiber meshes. PCL nanofiber meshes 
were electrospun on a flat collector plate. The mesh formed 50 was no significant difference between meshes and plates. On 
day 28, there was again no significant difference, though the 
lines crossed over. Although the hMSCs pellet in the plates 
and repopulate the culture surface by day 28, the amount of 
a circular area of approximately 8 cm diameter. The thick-
ness of the mesh was found to vary with location, with the 
central areas thicker than the edges. The thin mesh samples 
from the edges were discarded and not used for cell culture. 
Fibers appeared to be smooth and uniform, with minimal 55 
bead formation (FIGS. 7A and &B). The quantification of 
the fiber diameter using a custom MATLAB® program 
demonstrated that the mean fiber diameter was 591 nm with 
a standard deviation of 199 nm. The fiber diameter histo-
gram revealed that most of the fibers were between 300-900 
nm, with the highest frequency occurring in the 500-600 nm 
range (FIG. 7C). 
Viability and colonization ofhMSCs and hAFS cells over 
time. hMSCs and hAFS cells were seeded on electrospun 
nanofiber meshes and tissue culture plates, and cultured in 
osteogenic media for up to 28 days. The viability of the cells 
on the meshes was assessed on days 1, 7, 14 and 28 by the 
DNA was not significantly different than that on the mesh. 
Osteogenic differentiation of hMSCs and hAFS cells: 
ALP activity. The osteogenic differentiation of the cells was 
first investigated by analyzing the ALP activity of the cells 
(FIG. 9). ALP is a membrane-bound enzyme that hydrolyzes 
phosphate esters, which results in inorganic phosphate being 
60 available for incorporation into mineral deposits. There was 
significant increase in the ALP activity of both cell types 
with time, on plates as well on nano fiber meshes, suggesting 
osteogenic differentiation. On tissue culture plates, ALP 
activity peaked at day 7 for MSCs, whereas for AFS cells it 
65 increased slowly but continuously up to day 28 (FIG. 9A). 
Interestingly, the maximum ALP activity of the hAFS cells 
was greater than the hMSC peak. On the nanofiber meshes, 
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hMSCs demonstrated a similar earlier rise in ALP activity, 
on day 14, compared to day 28 for hAFS cells (FIG. 9B). 
The ALP activity of the hMSCs was significantly greater 
than that of hAFS cells on all time points other than day 1. 
The ALP response on meshes is delayed compared to that on 
the plate, as seen by the later increase in ALP activity. 
Interestingly, the ALP activity of hMSCs on meshes was 
sustained longer than plates, with the maximum value on 
meshes at day 28 greater than that observed on plates at day 
7 (p<0.05). 10 
Osteogenic differentiation of hMSCs and hAFS cells: 
matrix mineralization. The osteogenic differentiation of the 
cells was further investigated by quantifying and staining the 
calcium deposits and by analyzing the chemical nature of the 
deposited mineral by FTIR spectroscopy.AnANOVAon the 15 
calcium deposited by the cells revealed that both cell type 
and the culture surface had a significant effect on the calcium 
levels (FIG. 10). Under osteogenic stimulation, all groups 
demonstrated increased calcium deposition, compared to 
growth media, indicating that cells are able to differentiate 20 
to an osteoblastic phenotype on the surfaces. Calcium levels 
20 
the center of the top surface. A few cells were also seen in 
the interior of the scaffold, more than 500 µm away from the 
peripheral surface. The mesh was completely confluent with 
cells indicating that only a subset of cells migrates from the 
mesh onto the scaffold. 
Example 2 
Nanofiber Orientation and Surface 
Functionalization Modulate Human MSC 
Infiltration and Osteogenic Differentiation 
Electrospun nanofiber meshes are a unique type of scaf-
fold with structural features that, at least by scale, resemble 
the extracellular matrix (ECM). In addition, they exhibit 
large surface area and high porosity, making them suitable as 
a scaffold for guiding tissue regeneration by host cells. For 
example, in the case of a large diaphyseal bone defect, the 
nanofiber mesh may be able to provide cues for progenitor 
cells from the periosteum and marrow space to migrate into 
the defect region and deposit mineralized matrix. Example 
1 demonstrated that nanofiber meshes made from a synthetic 
polymer are able to support the attachment, colonization and 
osteogenic differentiation of progenitor cells. Synthetic 
in the hMSC growth media groups were negligible. hAFS 
cells deposited a higher amount of calcium than hMSCs on 
both plates and meshes. Also, both cell types deposited more 
calcium on meshes compared to plates. 25 polymers, however, lack biological ligands, and are not 
capable of directing intracellular signaling and response. 
Nanofiber meshes have also been fabricated from natural 
materials like collagen and fibrinogen, but these are limited 
FTIR spectroscopy was used to characterize the compo-
sition of the mineral that was deposited by the cells on the 
nanofiber meshes under osteogenic stimulation. To distin-
guish the peaks associated with the mineral from the peaks 
associated with the PCL mesh, an acellular piece of PCL 30 
mesh was also scanned. The cellular samples displayed 
amide I/II peaks at 1655 and 1550 cm- 1 , a carbonate peak at 
870 cm- 1 , and a doublet split phosphate peak at 560 and 605 
cm-1, which were not seen in the acellular mesh. There was 
also a peak at 1050 cm- 1 in the cellular samples, but it 35 
overlapped with a PCL mesh peak. These peaks are the 
signature of a carbonate-containing, poorly crystalline 
hydroxyapatite, the form of mineral that is found in native 
bone. This suggests that both hMSCs and hAFS cells 
deposited mineral that possessed the characteristic bands of 40 
physiological mineral. 
Samples were stained with calcein to visualize the pres-
ence of calcium on the nanofiber meshes. The calcein 
by poor mechanical strength and handling characteristics for 
in vivo applications. Approaches that incorporate bioactive 
molecules within a synthetic polymer backbone may provide 
an optimal combination of biological activity and mechani-
cal integrity. 
Tremendous advances have been made in imparting bio-
functionality to synthetic materials by coating them with 
ECM components. These biomimetic material surfaces pres-
ent adhesion motifs to engage the cell signal transduction 
machinery for directing cellular response and tissue repair. 
Though adhesive proteins such as type I collagen, fibronec-
tin and laminin have been immobilized on material surfaces, 
these approaches are limited by protein purification and 
staining demonstrated the presence of extensive calcium-
containing mineral nodules, which were uniformly distrib- 45 
uted on the meshes. This was the case in both the hMSC and 
processing issues, and a potential host immunogenic 
response. In addition, the multiple adhesion domains in a 
full-length protein may trigger conflicting intracellular sig-
nals, leading to suboptimal tissue repair. Therefore, there is 
a great need to develop peptides that mimic specific domains 
hAFS cell osteogenic groups, whereas the growth media 
groups stained minimally. Quantification of the fluorescence 
revealed that more mineral was deposited by the hAFS cells 
compared to the hMSCs (FIG. 11), thus supporting the 
calcium data. 
Nanofiber mesh as a cell delivery vehicle. As a prelimi-
nary evaluation of the nanofiber mesh for cell delivery, AFS 
cells were seeded on nanofiber meshes and wrapped around 
cylindrical collagen scaffolds in vitro. The constructs were 
cultured for two weeks and then stained with the Live/ 
Dead® staining kit. In the cell-seeded scaffold, more cells 
were present at the periphery of the scaffold, even though 
cells were seeded throughout. A large number of dead cells 
were also detected in the interior of the scaffold. When the 
cell-seeded mesh was wrapped around a collagen scaffold, 
we found that numerous cells had migrated off the mesh onto 
the collagen scaffold and had high viability. The majority of 
cells were located close to the peripheral surface. Interest-
ingly, we noted that the top surface was completely covered 
with cells. This implies that the cells were able to migrate at 
least 2 mm from the edge, where the mesh was present, to 
of natural proteins. These ECM-mimetic peptides can be 
synthesized and purified with relative ease, and furthermore, 
can be designed to trigger a specific cellular response. One 
50 such peptide that has been recently investigated is a triple-
helical, collagen-mimetic oligopeptide containing the gly-
cine-phenylalanine-hydroxyproline-glycine-glutamate-argi-
nine (GFOGER) domain from residues 502-507 of the a 1 (I) 
chain of type I collagen. It has been shown that the inter-
55 action of this adhesion motif with a2~ 1 integrin mediates 
osteoblast adhesion, differentiation and matrix mineraliza-
tion. This has been exploited to enhance the adhesion and 
osteogenic differentiation of progenitor cells and improve 
implant integration, by coating surfaces with the GFOGER 
60 peptide. This technique utilizes simple adsorption of the 
GFOGER peptide on implant surfaces in physiologic con-
ditions, which may be advantageous for clinical translation. 
Another set of guidance strategies consists of topographi-
cal cues to influence cellular responses. It is now accepted 
65 that surface morphology, including roughness and texture, 
modulates cellular response. For instance, titanium implants 
with rough microtopographies reduced cell number, 
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increased differentiation and enhanced implant integration. 
The electrospinning process can be easily adapted to obtain 
fibrous matrices with varying structure. Fiber alignment, 
especially, has generated significant interest due to the fact 
that a number of native and regenerating tissues display an 5 
ordered architecture. Studies have shown that alignment of 
fibers along a particular direction affects cellular attachment 
and morphology as well as matrix deposition. Neurites 
grown on aligned nanofibers display contact guidance and 
improved migration. However, the effect of fiber alignment 10 
on human MSCs (hMSCs) function needs to be investigated. 
random nanofiber meshes, the angles were measured with 
respect to an arbitrarily set line. 
GFOGER peptide preparation and nanofiber surface coat-
ing. The peptide, GGYGGGPC(GPP)5GFOGER 
(GPP)5 GPC, was synthesized by the Emory University 
Microchemical Facility (Atlanta, Ga.). This peptide contains 
the GFOGER motif, where 0 refers to hydroxyproline. The 
purified peptide was lyophilized as a trifluoroacetic acid 
(TFA) salt. The peptide was reconstituted at a concentration 
of 10 mg/mL in a 0.1 % TFA solution containing 0.01 % 
sodium azide (NaN3 ). The stock solution was diluted to 50 
µg/mL in phosphate-buffered saline (PBS, Mediatech Inc., 
Manassas, Va.). Nanofiber mesh samples were sterilized by 
ethanol evaporation, wetted with 70% ethanol and rinsed 
In addition, the combined effect of nanofiber mesh orienta-
tion and surface composition has not been studied exten-
sively. 
The purpose of this study was to investigate the effect of 
nanofiber functionalization and orientation on hMSC func-
tion, in order to identify conditions that best support bridg-
ing of bone defects by osteoprogenitor cells. Nanofiber 
meshes were functionalized with the GFOGER peptide to 
improve cell adhesion and osteogenic differentiation. An 
oriented topography was obtained by electrospinning 
aligned nano fibers in order to enhance cellular migration. An 
in vitro model was developed to examine hMSC infiltration 
on top of nanofiber meshes, and isolated the contribution of 
cell proliferation versus migration. The individual and com-
bined effects of nanofiber functionalization and orientation 
on hMSC function were investigated. In addition, the effi-
cacy of GFOGER coating to improve nano fiber mesh based 
repair of segmental bone defects in vivo was assessed 
Materials and Methods 
Electrospinning and nanofiber mesh characterization. 
15 with excess PBS. The samples were then passively adsorbed 
with GFOGER by submerging them in the dilute GFOGER 
solution for 2 hours at room temperature or overnight at 4° 
C. For comparison, samples were also coated with a 50 
µg/mL purified rat type I collagen (Trevigen Inc., Gaithers-
20 burg, Md.) solution or left uncoated in PBS. After rinsing 
again with PBS to remove any unbound peptide, the samples 
were ready for analysis or cell seeding. 
Analysis of GFOGER surface coating. The GFOGER 
adsorbed on the surface of the nanofibers was visualized and 
25 quantified using a biotinylated version of the GFOGER 
peptide. Biotin was conjugated to the carboxyl end of the 
peptide using the EZ-Link® Amine-PEG3 -Biotin kit (Pierce 
Biotechnology), and the unreacted biotin was removed by 
dialysis. To visualize the presence of the peptide on the 
30 nanofiber surface, the GFOGER coated nanofiber mesh 
samples were incubated with 10 µg/mL fluorescein conju-
gated NeutrAvidin® (Molecular Probes, Eugene, Oreg.) for 
30 minutes at room temperature in the dark. After rinsing 
with excess PBS, images were taken on an inverted fluo-
Nanofiber meshes were made by electrospinning, and char-
acterized as described in Example 1. Briefly, a 12% (w/v) 
solution of poly ( E-caprolactone) (PCL) was made in a 90: 10 
volume ratio of hexafluoro-2-propanol (HFP):dimethylfor-
mamide (DMF) (Sigma-Aldrich, St. Louis, Mo.). A 3 mL 
syringe (Becton-Dickinson, Franklin Lakes, N.J.) was filled 
with the PCL solution and fitted with a 22 gauge blunt-end 
needle (Jensen Global Inc., Santa Barbara, Calif.). The 
syringe was placed on a syringe pump (Harvard Apparatus, 
Holliston, Mass.), which was adjusted for a flow rate of0.75 
mL/hr. To create a nanofiber mesh with random fiber align-
ment (random nanofiber mesh), a flat copper plate was 
placed at a distance of 20-23 cm from the needle tip. To 
obtain meshes with fibers aligned along the same direction 
(aligned nanofiber mesh), they were collected on a mandrel 
rotating at -2500 rpm and placed 8-10 cm from the need tip. 
The syringe needle was attached to the positive end of a high 
voltage power supply (Gamma High Voltage Research, 
Ormond Beach, Fla.), and the collector was grounded to 
create the electrostatic field required for electrospinning. 
After applying a voltage of 13-20 kV, the polymer solution 
was ejected from the needle towards the collector and 
deposited as nano-scaled fibers. The fibers were collected for 55 
45-60 minutes to obtain meshes with sufficient thickness for 
35 rescence microscope (Axio Observer.Zl, Carl Zeiss, Thom-
wood, N.Y.) using a FITC filter. The saturation of the surface 
by GFOGER was investigated by incubating meshes with 
varying GFOGER concentrations of 0-50 µg/mL. To quan-
tify the amount of the biotinylated GFOGER peptide 
40 adsorbed on the nanofiber surface, an ELISA was performed 
using an anti-biotin antibody. Non-specific adsorption of the 
antibody was first blocked by immersing the nanofiber 
meshes in 0.25% heat denatured serum albumin with 
0.0005% Tween-20, 1 mM EDTA, and 0.025% NaN3 in PBS 
45 for 1 hour at 37° C. The meshes were then incubated with 
an anti-biotin antibody (diluted 1:2000) conjugated to alka-
line phosphatase (clone BN-34, Sigma-Aldrich) for 1 hour at 
37° C. An alkaline phosphatase substrate, 4-methylumbel-
liferyl phosphate, was used at a concentration of 60 µg/mL 
50 in diethanolamine buffer (pH 9.5) to measure the amount of 
bound antibody. After incubating the meshes with the sub-
strate solution for 1 hour at 37° C., the fluorescence was read 
on a plate reader (HTS 7000, Perkins-Elmer, Waltham, 
Mass.) at an excitation of 360 nm and emission of 465 nm. 
Human mesenchymal stem cell (hMSC) culture. Briefly, 
bone marrow aspirates were taken from the iliac crest of 
normal adult donors, the nucleated cells were isolated with 
a density gradient and only the cells that adhered to the plate 
after 24 hours were cultured further. Passage 1 cells frozen 
cell culture experiments. 
The nanofiber meshes were sputter coated with gold 
(Quorum Technologies, East Granby, Conn.) and their mor-
phology visualized by Scanning Electron Microscopy 
(SEM; Hitachi HTA, Pleasanton, Calif.). A custom MAT-
LAB® (The Math Works Inc., Natick, Mass.) program was 
used to calculate the individual fiber diameter from the SEM 
images. The alignment of the fibers in aligned nanofiber 
meshes was quantified by measuring fiber angle relative to 
the direction of rotation, using the Image-Pro software 
(Media Cybernetics, Inc., Bethesda, Md.). In the case of 
60 in 1 mL aliquots were shipped us. To expand a culture, the 
cells were thawed and plated at a density of 50 cells/cm2 in 
aMEM (Invitrogen), supplemented with 16% FBS (Atlanta 
Biologicals, Atlanta, Ga.), 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2 mM L-glutamine (Invitrogen). This is 
65 termed the hMSC growth media. After the cells reached a 
confluency of - 70%, they were harvested with 0.25% 
trypsin-EDTA (Invitrogen), counted, and either expanded 
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again or seeded on nanofiber meshes. Passage 2-3 hMSCs 
were used in all experiments. 
24 
40,000 cells/cm2 , as above. Twenty four hours post seeding, 
mitomycin C was added to the media at a final concentration 
of 10 µg/mL, and incubated for 60 minutes. The media was 
slowly aspirated, fresh media was added and the stainless 
strip was removed. After a further 48 hours, the samples 
were taken down, stained with DAPI and analyzed for cell 
infiltration into the gap. 
Osteogenic differentiation and total DNA content on 
nanofiber meshes. Random and aligned nanofiber mesh 
Investigating cell infiltration on nanofiber meshes in an in 
vitro model. Rectangular samples (8 mmx12 mm) were cut 
from random and aligned nanofiber mesh sheets, sterilized 
and coated with GFOGER or collagen, or left uncoated in 
24-well tissue culture plates, as mentioned above. A 0.9 mm 
wide sterile stainless steel strip was then placed on the 
nanofiber mesh to create a region without cells (FIG. 12). 
For aligned nanofiber meshes, the strip was placed perpen-
dicular to the fiber orientation. Samples were submerged in 
800 µL of hMSC growth media, after placement of a dead 
weight on the edges to prevent them from floating. hMSCs 
were then seeded on the nanofiber mesh samples at a density 
of 40,000 cells/cm2 in 200 µL ofhMSC growth media. After 
24 hours, the strip was removed, and the cell infiltration into 
the gap was observed at various time points. 
10 samples were coated with GFOGER, collagen, or left 
uncoated. hMSCs were seeded on circular mesh samples 
(diameter: 12 mm), cut using biopsy punches (Acuderm, Ft. 
Lauderdale, Fla.), at a density of20,000 cells/cm2 . Four days 
after seeding, the hMSC growth media was replaced with 
Cell infiltration was analyzed by staining the nuclei with 
4',6-diamidino-2-phenylindole (DAPI, Molecular Probes). 
Some samples were, in addition, stained with rhodamine 
phalloidin (Molecular Probes) to visualize the cell align-
ment. After samples were taken down, they were rinsed with 
PBS and fixed with 4% formaldehyde for 10 minutes. The 
samples were then incubated in 0.05% Triton-X (Sigma-
Aldrich) for 5 minutes, rinsed in PBS and incubated in 5 
units/mL rhodamine phalloidin for 20 minutes. After a PBS 
rinse step, the samples were incubated in 5 µg/mL DAPI for 
15 osteogenic media, which consists of the hMSC growth 
media supplemented with 10 nM dexamethasone, 6 mM 
~-glycerol phosphate, 50 µg/ml ascorbic acid 2-phosphate 
and 50 ng/ml L-thyroxine (Sigma-Aldrich). Media was 
changed every 3-4 days and the samples were cultured for 3 
20 weeks. The samples were analyzed for DNA content, alka-
line phosphatase (ALP) activity and calcium deposition, as 
described previously in Example 1. Briefly, cells were lysed 
by freeze-thawing three times. The cell extract was used to 
measure DNA amount by the PicoGreen® dsDNA Quanti-
25 tation Kit (Molecular Probes) and ALP activity by the use of 
p-nitrophenyl phosphate. The calcium content of a separate 
set of mesh samples was determined by using the dye 
Arsenazo III, after overnight incubation in 1 N acetic acid. 5 minutes. Samples were finally washed in excess PBS to 
remove any unbound dye, and images were taken on an 
inverted fluorescence microscope (Carl Zeiss). The DAPI 30 
images were further processed using ImageJ (U.S. National 
Institutes of Health, Bethesda, Md.) to count the cell nuclei, 
and thereby quantify cell number. Three fields of view along 
the gap were analyzed for each sample, and the mean cell 
number per field is presented, along with the standard error 35 
of the mean. To investigate the number of cells attached on 
day 0, four locations outside the gap were analyzed. 
Role of cell proliferation in the cell infiltration model. To 
investigate whether cell proliferation influences the infiltra-
tion of cells on nanofiber meshes, mitomycin C was used to 40 
block proliferation. Mitomycin C, which is a known inhibi-
tor of cell proliferation, cross links the strands of DNA, 
thereby inhibiting DNA replication. The effect ofmitomycin 
C on hMSC proliferation was first studied on tissue culture 
plates. hMSCs were plated at a density of 20,000 cells/cm2 , 45 
and after 24 hours, they were incubated with 10 µg/mL 
mitomycin C for 60 minutes. Control samples remained in 
culture media. Cell proliferation was assessed using 
5-bromo-2'-deoxyuridine (BrdU) labeling, according to the 
manufacturer's instructions (FLUOS, Roche Diagnostics, 50 
Mannheim, Germany). Forty eight hours after cell seeding, 
the cells were incubated in hMSC growth media containing 
10 µM BrdU for 24 hours in the incubator. Cells were fixed 
with an ethanol based fixative for 45 minutes, and denatured 
with 4 M HCl for 20 minutes to allow for antibody access. 55 
After neutralizing the pH with PBS, the cells were incubated 
with a monoclonal anti-BrdU-antibody conjugated with 
fluorescein for 45 minutes at 37° C. The cells were finally 
stained with DAPI for the total number of cells and analyzed 
using fluorescence microscopy, as mentioned above. Nine 60 
fields were examined in a 3x3 grid pattern, and the number 
of BrdU positive cells along with the DAPI stained cells 
were counted. Data are presented as the BrdU and DAPI cell 
counts, as well as the proportion of BrdU positive cells. 
The effect of mitomycin C was next studied in the cell 65 
infiltration model on nanofiber meshes. Cells were seeded 
on rectangular nanofiber mesh samples at a density of 
Assessment of GFOGER coated nanofiber meshes in 
vivo. Nanofiber meshes were used to create tubular 
implants, having a diameter of approximately 5 mm and a 
length of 13 mm, without any perforations. The mesh tubes 
were coated with 50 µg/mL GFOGER overnight at 4° C., 
while control samples were left in PBS. Female Sprague-
Dawley rats aged 13 weeks were used for this study. Both 
femurs were stabilized by fixation plates, and 8 mm seg-
mental defects were created in the mid-diaphyses. Nanofiber 
mesh tubes were rinsed with PBS, and implanted in the 
defect, such that the periphery of the defect was covered 
with nanofiber mesh with the center empty. 
Radiographs were obtained at 4 and 12 weeks, and ex 
vivo µCT analysis was performed at 12 weeks to detect bone 
formation. Torsional testing was performed on extracted 
femurs at 12 weeks to test their biomechanical properties. 
Histological analysis consisted of embedding in glycol 
methacrylate (GMA), obtaining 5 µm sections, and staining 
with H&E. 
Data analysis. Data were analyzed using ANOVA and 
Tukey's tests for pairwise comparisons. Whenever required, 
the raw data was transformed using a natural logarithmic 
transformation to make the data normal and the variance 
independent of the mean. Student's t-test was used for 
2-sample comparisons, where it was appropriate. Other 
statistical tests that were performed for specific comparisons 
are mentioned in the results section. The significance level 
for the above analyses was set at p<0.05. Minitab® 15 
(Minitab Inc., State College, Pa.) was used for all statistical 
analysis. 
Results 
Nanofiber mesh morphology and alignment. PCL nano-
fiber meshes were produced by electrospinning and charac-
terized by analyzing SEM images. Interconnected, non-
woven fibers that were mostly bead-free were obtained (FIG. 
1). The resulting nanofiber mesh is a porous structure, but 
due to the multiple fiber layers, the effective pore size 
appeared to be less than 2 µm, much less than hMSC 
dimensions. A flat stationary collector was used to obtain 
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random nanofiber meshes with no dominant fiber orienta-
tion. The mean and median fiber diameters for random 
meshes were found to be 168.0 nm and 122.8 nm respec-
tively. The distribution of fiber diameters indicated that the 
highest frequency occurred for fibers between 75 nm to 125 5 
nm, with 90% of the fibers between 50-300 nm. To obtain 
aligned nanofiber meshes, a rotating mandrel was used to 
orient the fibers along the direction of rotation of the 
mandrel surface (FIG. 2A). In this case, the mean and 
median fiber diameters were observed to be 256.4 nm and 10 
227.4 nm. The fibers of the aligned meshes were found to be 
significantly larger in diameter than those in the random 
meshes (Marni-Whitney test; p<0.001). The angle of the 
fibers with respect to an arbitrary line was measured to 
quantify fiber alignment (FIG. 2B). Though there is a 15 
moderate spread in the orientation of the fibers, a preferred 
fiber direction was observed, with 89% of the fibers between 
-45 to 45°. For random meshes, this metric was calculated 
26 
whether GFOGER coating had a significant effect on cell 
attachment efficiency, we counted the cells that attached 
outside the gap on day 0. The cell counts were observed to 
be equivalent in both the uncoated and GFOGER coated 
groups, indicating that GFOGER coating did not modify the 
cell attachment efficiency (FIG. 13B). This implies that both 
sets of samples start with comparable number of cells on the 
gap border. 
The ability of GFOGER coating and fiber alignment to 
enhance cellular infiltration in this model was next studied 
on day 2 after strip removal. Some samples were coated with 
collagen to compare to the collagen-mimetic GFOGER 
peptide. The DAPI images revealed that the gaps on the 
GFOGER coated meshes were completely confluent with 
cells. Aligned and collagen coated meshes displayed mod-
erately more cell infiltration than random and uncoated 
meshes, respectively. The cell numbers were determined in 
two regions: the entire gap and the middle-third of the gap. 
The middle-third region of the gap was analyzed as a more 
stringent measure of cellular infiltration. Analysis of the cell 
counts indicates that both coating and fiber alignment had a 
significant effect on cell infiltration in both the regions (FIG. 
14). In the entire gap region on random meshes, GFOGER 
coated samples displayed higher cell numbers, compared to 
to be only 52%. Using a Z test for proportions, the alignment 
was found to be significantly higher in the case of aligned 20 
meshes (p<0.0001). hMSCs seeded on aligned nanofiber 
meshes exhibited a polarized morphology along the pre-
ferred fiber direction, while in the case of random nano fiber 
meshes, the cells did not display any regular orientation 
(FIG. 3C). 
GFOGER coating of nanofiber meshes. The collagen-
mimetic peptide: GGYGGGPC(GPP)5 GFOGER(GPP)5 
GPC, containing the GFOGER motif, was synthesized by 
stepwise solid-phase procedures. The amino acid sequences 
adjacent to GFOGER enable formation of a stable right- 30 
handed triple helical configuration, which is required for cell 
adhesion. The GFOGER peptide was passively adsorbed on 
the surface of nanofiber meshes at a concentration of 50 
µg/mL. The adsorbed peptide was visualized by coating the 
meshes with a biotinylated GFOGER peptide and incubating 35 
in a fluorescein conjugated NeutrAvidin®. The images 
revealed that the peptide coated the individual fibers uni-
formly over the entire mesh area. An ELISA was performed 
25 both uncoated and collagen samples. On the aligned meshes, 
both GFOGER and collagen coated samples had higher cell 
counts than the uncoated samples. Fiber alignment enhanced 
cell infiltration on uncoated and collagen coated samples. 
to quantify the amount of the GFOGER peptide adsorbed on 
the nanofibers with varying peptide concentration. The satu- 40 
ration curve indicated that the relative surface density 
increased with increasing peptide concentration, with the 
surface being saturated at a concentration of approximately 
20 µg/mL. The peptide concentration at which the surface is 
50% saturated, was calculated to be 3.45 µg/mL. For all 45 
further experiments, a peptide concentration of 50 µg/mL 
was used to ensure saturation of the surface for maximal 
biologic response. 
Cellular infiltration on nanofiber meshes. An in vitro 
model was developed to study the effect of GFOGER 50 
coating and fiber alignment on cellular infiltration on top of 
nanofiber meshes. A cell-free region was created on the 
mesh, and the infiltration of hMSCs into this gap was 
examined by analyzing the DAPI stained images. To observe 
baseline infiltration, we first performed the experiments with 55 
uncoated, random nanofiber meshes (FIG. 13A). A cell-free 
region was generated in day 0 samples. The mean gap width 
was found to be 0.874±0.02 mm, which was slightly less 
than the width of the stainless steel strip (0.9 mm). The 
number of cells in the gap were counted on days 0, 3, 4 and 60 
5. The cell count in the gap was found to be negligible on 
day 0. The quantification of cell infiltration revealed that 
there were significantly more cells in the gap on days 3 and 
4 compared to day 0, and on day 5 compared to days 3 and 
4 (p<0.05). The gap was not completely confluent with cells, 65 
even at day 5, indicating a slow infiltration rate on the 
uncoated and random nanofiber meshes. To investigate 
However, this effect was not seen on the GFOGER coated 
meshes, probably due to the fact that the gap was saturated 
with cells, even on the GFOGER coated, random meshes. 
Analysis of the middle-third region of the gap revealed that 
the cell counts displayed the following order for both 
random and aligned meshes: 
GFOGER>Collagen>Uncoated. Fiber alignment enhanced 
the cell infiltration on both uncoated and collagen coated 
samples, similar to the observation in the entire gap. 
Effect of cell proliferation on the infiltration of cells on 
nanofiber meshes. The cell infiltration observed on nanofiber 
meshes could be due to the migration and/or proliferation of 
hMSCs. To assess the contribution of cell proliferation, 
proliferation was blocked by treating the cells with mito-
mycin C, a known inhibitor of cell proliferation, 24 hours 
after seeding. Mitomycin C was verified to inhibit prolif-
eration of hMSCs on tissue culture plates by staining with 
BrdU, a marker of cell proliferation. The results demonstrate 
that 48 hours after mitomycin incubation, the number of 
proliferating cells (seen with BrdU staining) decreased, 
thereby reducing the total number of cells (seen with DAPI 
staining) at this time point. In the absence of mitomycin C, 
the proportion of proliferating cells during the 24 hour 
period was 84.1 %. This proportion decreased significantly to 
6.4% in the presence of mitomycin C, indicating that mito-
mycin C blocked proliferation in almost all hMSCs. 
The effect of inhibiting cell proliferation on the infiltration 
of hMSCs on nanofiber meshes was next investigated. 
hMSCs were seeded on nanofiber meshes, with a stainless 
steel strip placed on top, and allowed to attach for 24 hours 
(FIG. 15A). The cells were incubated with mitomycin C for 
60 minutes, and the strip was removed. After 48 hours of 
strip removal, the samples were stained with DAPI and 
analyzed for cell infiltration (FIG. 15B). The analysis of both 
the entire gap and the middle-third gap regions revealed that 
in the absence of mitomycin C, both GFOGER coating and 
fiber alignment enhanced cell infiltration, as observed 
before. With mitomycin C incubation, the overall cell infil-
tration decreased, indicating that cell proliferation contrib-
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uted significantly to the infiltration. In the presence of 
mitomycin C, only the aligned, uncoated mesh samples had 
a significantly higher cell count than the random, uncoated 
mesh samples, in the entire gap region. In contrast, in the 
middle-third of the gap, the random, GFOGER-coated 5 
samples demonstrated significantly higher infiltration than 
the random, uncoated samples. Furthermore, the aligned, 
uncoated group displayed a higher cell count than the 
random, GFOGER-coated group. These results suggest that 
both cell proliferation and migration contribute to the 10 
observed cell infiltration on meshes, and that proliferation 
has a larger influence on infiltration due to GFOGER coat-
ing, compared to fiber alignment. 
Influence of nanofiber coating and alignment on total 
DNA content and osteogenic differentiation. Cells were 15 
seeded on circular nanofiber meshes and cultured in either 
hMSC growth or osteogenic media up to 21 days. This 
culture system does not involve the use of a stainless steel 
strip, and the cells are uniformly distributed on the mesh. 
First, the effect of GFOGER coating on changes in cell 20 
number was studied by measuring the amount of DNA 
extracted from the samples at days 4 and 7. The results 
demonstrate that GFOGER coating increased the amount of 
DNA in osteogenic media samples at both days 4 and 7, 
suggesting an improved proliferation rate (FIG. 16). GFO- 25 
GER coating did not have a significant effect on amount of 
DNA in growth media. The effect of coating and fiber 
alignment on DNA content in osteogenic media was inves-
tigated at a later time point of 21 days. AN OVA revealed that 
coating had an overall significant effect on amount of DNA, 30 
but there were no significant individual differences between 
the groups (FIG. 17 A). 
The influence of nanofiber coating and alignment on the 
osteogenic differentiation of hMSCs in osteogenic media 
was studied by measuring the ALP activity and calcium 35 
deposition. Analysis of the ALP activity data revealed that 
both coating and fiber alignment had a significant effect on 
ALP activity, and that the GFOGER-coated samples dis-
played an overall higher ALP activity than the uncoated and 
collagen coated groups (FIG. 17B). In the case of random 40 
nanofiber meshes, the GFOGER group also demonstrated 
significantly higher ALP activity than the uncoated and 
collagen groups, whereas, on aligned meshes, the GFOGER 
group displayed significantly higher activity than the colla-
gen group only. Fiber alignment was found to reduce the 45 
ALP activity, in the case of GFOGER- and collagen-coated 
samples. 
Under osteogenic stimulation, hMSCs deposited calcium 
on the nanofiber meshes, indicative of an osteoblast pheno-
type (FIG. 17C). GFOGER coating significantly enhanced 50 
calcium deposition on both random and aligned meshes, 
compared to uncoated meshes. In addition, on random 
meshes, GFOGER-coated samples demonstrated signifi-
cantly higher calcium deposition than collagen-coated 
samples. Collagen coating increased calcium levels only in 55 
the case of aligned meshes. Fiber alignment did not have an 
overall significant effect on calcium deposition, though a 
reduction was observed in the case of uncoated meshes. 
Assessment of GFOGER coated nanofiber meshes in 
vivo. To investigate the ability of GFOGER coated nano fiber 60 
meshes to enhance bone formation in vivo, tubes made from 
nano fiber meshes were coated with the GFOGER peptide, or 
left uncoated, and implanted around segmental bone defects 
created in rat femurs. Radiographs at 4 and 12 weeks 
displayed new bone formation near the ends and the periph- 65 
ery of the defect (FIG. 18). However, none of the defects 
were bridged completely. The results of the µCT analysis 
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and torsional testing at 12 weeks revealed no significant 
differences between the two groups, indicating that coating 
nanofiber mesh tubes with GFOGER did not enhance bone 
formation in this model (FIG. 19). The cross sectional views 
of the µCT images illustrated some bone formation along the 
nanofiber mesh tube and at the native bone boundary. 
However, capping of defect ends was observed, and pres-
ence of bony tissue was not evident at the defect center. 
Histological analysis of the defect area confirmed capping of 
the defect ends with newly formed bone (FIG. 20). A 
combination of newly formed bone, fibrous tissue and 
marrow was seen within the defect. 
Example 3 
A Novel Hybrid System for Growth Factor 
Delivery Promotes Functional Repair of Large 
Bone Defects 
The primary objective of this Example was to develop and 
test a hybrid growth factor delivery system for bone repair 
that utilizes an electrospun nanofiber mesh and injectable 
alginate hydrogel. To test this system, we evaluated its 
ability to deliver rhBMP-2 for the repair of critically-sized 
segmental bone defects in vivo. For control group compari-
sons, we also examined the ability of the nanofiber mesh 
alone, and in combination with alginate hydro gel, to heal the 
bone defects without rhBMP-2. Finally, the effect of a 
perforated nanofiber mesh design on bone repair was inves-
tigated. 
Materials and Methods 
Fabrication of nanofiber mesh tubes. Poly (E-caprolac-
tone) (PCL) pellets (Sigma-Aldrich, St. Louis, Mo.) were 
dissolved in a 90:10 volume ratio ofhexafluoro-2-propanol 
(HFP):dimethylformamide (DMF) (Sigma-Aldrich) to 
obtain a 12% (w/v) polymer solution. DMF was first slowly 
added to HFP to prevent excessive heat generation, and 
mixed well on a stir plate for 5 minutes. The PCL pellets 
were then added to the solvent solution, and gently stirred 
for 16-24 hours. The solution was visually inspected to 
ensure a homogeneous and clear solution. The polymer 
solution was loaded in a 3 mL syringe (Becton-Dickinson, 
Franklin Lakes, N.J.), and a 22 gauge blunt stainless steel 
needle (Jensen Global Inc., Santa Barbara, Calif.) was 
attached to the syringe end. The syringe was mounted on a 
syringe pump (Harvard Apparatus, Holliston, Mass.) set at a 
rate of0.75 mL/hr. The fibers were collected on a flat copper 
plate (McMaster-Carr, Atlanta, Ga.) which was placed at a 
distance of 20-23 cm from the needle end. Fibers were 
electrospun for 5 hours at a voltage of 13-20 kV, supplied by 
a high voltage power supply (Ganima High Voltage 
Research, Ormond Beach, Fla.), to obtain a thick sheet of 
nanofiber mesh. The residual solvent from the meshes was 
allowed to evaporate by placing them in a dessicator over-
night. The morphology of the nanofiber meshes was exam-
ined using a Scanning Electron Microscope (SEM; Hitachi 
HTA, Pleasanton, Calif.) after gold coating using a sputter 
coater (Quorum Technologies, East Granby, Conn.). The 
diameter of the fibers were quantified by analyzing the SEM 
images (at 7000 magnification) using a custom MATLAB® 
(The Math Works Inc., Natick, Mass.) code. 
The nanofiber meshes, as fabricated above, were used to 
create tubular implants. Rectangular samples measuring 
13x19 mm were cut from a mesh. In some samples, perfo-
rations spaced approximately 1.5 mm apart were made in the 
mesh using a 1 mm diameter biopsy punch (Miltex Inc., 
York, Pa.). The rectangular mesh samples were wrapped 
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amount of rhBMP-2 present in the collected PBS and 
sodium citrate solution was quantified using an ELISA kit 
(R&D Systems), following the manufacturer's instruction. 
Surgical procedure and analysis. An established critically-
sized, femoral segmental defect rat model was used in this 
study. All surgical procedures were approved by the Insti-
tutional Animal Care and Use Committee (IACUC protocol 
#A05041) at the Georgia Institute of Technology. The rat 
model and surgical technique has been described previously. 
Briefly, bilateral 8 mm segmental defects were created in the 
mid femoral diaphyses of 13-week old female Sasco 
Sprague-Dawley rats. Prior to defect creation, the femora 
were stabilized by modular fixation plates consisting of a 
polysulfone plate and two stainless steel plates. This is a 
around a steel mandrel (McMaster-Carr) to form a tube 
having a diameter of approximately 5 mm and 13 mm 
length. The overlapping edges of the mesh were secured 
together by using UV glue (DYMAX Corporation, Tor-
rington, Conn.), which was cured with a LED spot curing 5 
lamp (DYMAX Corporation). The nanofiber mesh tubes 
were then rinsed twice in 70% alcohol (VWR, West Chester, 
Pa.), and sterilized by submerging in 200 proof ethanol 
(Sigma-Aldrich) and allowing the ethanol to evaporate over-
night. After the samples had dried completely, they were 10 
pre-wetted with sterile 70% ethanol for 30 minutes. After 
aspirating the 70% ethanol, the mesh tubes were rinsed three 
times with excess phosphate-buffered saline (PBS; Mediat-
ech Inc., Manassas, Va.), and placed in aMEM (Invitrogen) 
until implantation. 
Preparation of Alginate Hydrogel with and without 
Growth Factors. Briefly, Irradiated RGD-modified alginates 
were prepared by subjecting MVG sodium alginate (FMC 
Biopolymer) to a 5 Mrad dose of gamma irradiation. This 
reduces the molecular weight of the polymer leading to a 20 
faster degradation rate, which makes it more appropriate for 
15 more challenging segmental defect model compared to the 
5-6 mm defect models that are used most frequently in the 
field. Nanofiber mesh tubes were placed around the adjacent 
bone ends such that the tube lumen contained the defect and 
in vivo studies. The irradiated alginates were then covalently 
coupled with G4 RGDASSP peptide sequences (Common-
wealth Biotechnologies, Richmond, Va.) at a density of 2 
sequences per polymer chain using standard carbodiimide 25 
chemistry. The resulting RGD-alginates were sterile filtered, 
lyophilized and stored at -20° C. 
To prepare hydrogels, the RGD-alginates were reconsti-
tuted in a-MEM to obtain a 2.5% (w/v) solution. 
Lyophilized rhBMP-2 (R&D Systems, Minneapolis, Minn.) 30 
was reconstituted in 0.1% rat serum albumin (RSA; Sigma-
Aldrich) made in 4 mM HCl, at a concentration of 200-µg/ 
mL. The alginate solution was then mixed with either the 
rhBMP-2 solution at a ratio 5: 1 (700-µL alginate solution 
@2.5% (w/v) with 175-µL rhBMP-2 @200-µg/mL or 0.1 % 35 
RSA). This results in a 2% (w/v) alginate solution contain-
ing 40-µg/mL rhBMP-2. The rhBMP-2 containing alginate 
solution was cross-linked with a calcium sulfate (Sigma-
Aldrich) slurry (0.21 g CaS04 per 1 mL deionized water) at 
a ratio of 25:1 (35 µL of CaS04 with 875 µL of alginate/ 40 
rhBMP-2 solution). The mixing was performed in two 1-mL 
syringes (Becton-Dickinson, Franklin Lakes, N.J.) coupled 
with a syringe connector (Cole-Parmer, Vernon Hills, Ill.) 
with Luer-Lok fittings to minimize air bubbles. Another set 
ofhydrogels was prepared without rhBMP-2 by substituting 45 
the rhBMP-2 solution with the carrier (0.1 % RSA) alone. 
The alginate solutions were allowed to gel in the syringes for 
30 minutes at room temperature and then transferred to 4 ° C. 
The hydrogels were kept at 4° C. overnight and used in 
surgery the following day. Aseptic conditions were main- 50 
tained in all the above steps, including handling of the 
exterior of the syringe. 
rhBMP-2 release kinetics. RGD-alginate solutions con-
taining rhBMP-2 were cross-linked with a calcium sulfate 
slurry as above, and immediately injected into custom 55 
designed molds containing 4 mm diameter wells. The alg-
inate solutions were allowed to gel for 30 minutes at room 
temperature, producing cylindrical plugs measuring 4 mm in 
diameter and 8 mm in length. Each cylindrical alginate plug 
contained 500-ng rhBMP-2. Following a brief rinse in 0.1 M 60 
CaCl2 (Sigma-Aldrich), the samples were incubated at 37° 
C. in 1-mL PBS containing calcium and magnesium ions. At 
specific time points through day 21, the entire buffer solution 
was collected and replaced with fresh 1-mL PBS. On days 
0 and 21, alginate plugs were dissolved by immersing in 65 
8-mL and 2-mL, respectively, of 2% (w/v) sodium citrate 
(Sigma-Aldrich) for 30 minutes at room temperature. The 
there was an overlap of 2.5 mm with the native bone ends 
at each end of the tube. In some groups, 125-µL pre-gelled 
2% alginate with or without 5-µg rhBMP-2 was injected in 
the tube lumen using a 22 g needle (Jensen Global Inc.). As 
it is a soft hydrogel, the pre-gelled alginate is ejected from 
the needle in a continuous thin filament shape and fits 
compactly inside the tube. The tubes used for one of the 
groups had 1 mm diameter perforations to enhance vascular 
invasion during the repair process. The four groups (n=6-8) 
were as follows: (I) Mesh alone, (II) Mesh with alginate, 
(III) Mesh with alginate containing rhBMP-2, (IV) Table 1 
provide the four groups utilized in the in vivo study, with the 
implant conditions in each group. 
Perforated mesh with alginate containing rhBMP-2. The 
groups were assigned to the right and left limbs to evenly 
distribute pairs of groups and obtain a balanced experimen-
tal design. After surgery, the animals were allowed to 
recover and move freely. For pain relief, the animals were 
injected with 0.03 mg/kg buprenorphine subcutaneously 
every 8 hours for the first 48 hours and 0.01 mg/kg buprenor-
phine for the next 24 hours. Radiographs and in vivo 
micro-computed tomography (µCT) images were obtained 
at 4 and 12 weeks after surgery to evaluate bone healing. The 
rats were euthanized at 12 weeks and femora were extracted 
for mechanical testing. Histological analysis was performed 
on femora extracted at 4 and 12 weeks. 
TABLE 1 
Group Nanofiber rhBMP-
# mesh tube Perforations Alginate 2 
+ 
II + + 
III + + + 
IV + + + + 
2-D radiographs and 3-D in vivo µCT imaging. At 4 and 
12 weeks after implantation, two-dimensional radiographs 
(Faxitron MX-20 Digital, Faxitron X-ray Corp., Wheeling, 
Ill.) of the femur were taken to qualitatively assess bone 
regeneration and defect bridging. For the quantitative evalu-
ation of bone formation, in vivo µCT was performed at the 
same time points. The rats were anesthetized by isoflurane 
and placed in an in vivo µCT system (Viva-CT, Scanco 
Medical, Bassersdorf, Switzerland). The femoral defect 
region was scanned at a 38.5-µm voxel resolution, a voltage 
of 55-kVp and a current of 109-p A. The radiotranslucent 
polysulfone plate does not interfere with µCT scanning and 
therefore allows longitudinal evaluation of bone ingrowth. 
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To obtain a consistent volume of interest (VOI) between 
animals and to avoid including the native bone ends, only 
the central 4 mm of the 8 mm defect was analyzed in vivo 
by drawing circular contours. A Gaussian filter (sigma=l.2, 
support=!) was used to suppress noise in the VOI, and a 5 
global threshold corresponding to a density of 270.3 mg 
hydroxyapatite/cm3 was applied to obtain the regenerated 
bone volume. This threshold was selected by the visual 
inspection of individual scan slices to detect newly formed 
bone and to exclude soft tissues, the polysulfone fixation 10 
plate and the nanofiber mesh tube. The volume and density 
of the segmented bone was noted. In addition, the density 
map was calculated in the segmented bone volume, and 
presented as a pseudo color-scaled image. 
Torsional testing. The freshly extracted femora at 12 15 
weeks were wrapped in gauze moistened with PBS, and 
stored at -20° C. Just before testing, samples were thawed 
in PBS and the majority of soft tissues adjacent to the bone 
removed. The ends of the femur were embedded in end 
blocks using Wood's metal (Alfa Aesar, Wood Hill, Mass.) 20 
and aligned using a custom fixture. The polysulfone plate 
was then detached from the metal plates to enable loading of 
the bone. The potted femur was loaded into holding brackets 
mounted on a Bose ElectroForce system (ELF 3200, Bose 
EnduraTEC, Minnetonka, Minn.) fitted with a 2 Nm tor- 25 
sional load cell. The samples were rotated to failure at a rate 
of3° per second under displacement control, and the torque 
and rotation were recorded. Maximum torque was calculated 
by locating the failure torque, which occurred within the first 
15° for bridged defects. Samples that did not bridge dis- 30 
played a gradual increase in torque and the absence of a 
sharp failure point, due to soft tissue stretching. For these 
samples, the failure torque was measured in the first 60° to 
avoid analyzing the forces generated due to the stretching of 
soft tissues. Stiffness was calculated by finding the slope of 35 
the straight line fitted to the linear portion of the torque-
rotation plot before failure. 
Histological analysis. One representative sample from 
each group was selected for histological evaluation at 4 and 
12 weeks. The extracted femora were fixed in 10% neutral- 40 
buffered formalin for 48 hours. They were dehydrated in a 
series of alcohol solutions of increasing concentrations, 
infiltrated with methyl methacrylate (MMA), and embedded 
by polymerizing the MMA. Ground sections, 50-80 µm 
thick, were generated using a EXAKT Grinding System 45 
(EXAKT Technologies, Oklahoma City, Okla.). The sec-
tions were stained with Sanderson's Rapid Bone Stain and 
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Fisher Scientific). The samples were rinsed in PBS and 
stored in 10% neutral buffered formalin until imaging. They 
were imaged in a µCT system (Viva-CT, Scanco Medical) at 
a 21.5-µm voxel size. Two VOis were defined to analyze the 
vessels inside the defect and adjacent to the defect. The 
images were globally thresholded based on X-ray attenua-
tion to segment the contrast-filled vasculature from sur-
rounding tissues. 
Statistical analysis. Data were analyzed by analysis of 
variance (ANOVA) conducted in Minitab® 15 (Minitab 
Inc., State College, Pa.). Pairwise comparisons were made 
using the Tukey multiple comparison procedure. The nor-
mality of the residuals was evaluated by the Anderson-
Darling normality test. To detect the presence of any pattern 
in the residual distribution, they were plotted against fitted 
values. To maintain the constancy of error variance and 
normality of error terms, data were transformed according to 
the Box-Cox procedure, wherever required. To investigate 
the effect of time on sequential in vivo µCT data, paired 
t-tests were performed. A p-value<0.05 was considered 
statistically significant. All data are shown as 
mean±standard error of mean (SEM). 
Results 
Nanofiber mesh tube characterization and placement. The 
nanofibers obtained by electrospinning were observed to be 
smooth and bead-free (FIG. 21A). The fibers ranged in 
diameter from 51 nm to 974 nm with 82% of the fibers 
between 50 nm and 150 nm. The mean and the median fiber 
diameter were found to be 154 nm and 107 nm respectively. 
After 5 hours of electrospinning, the mesh was found to be 
approximately 300-400 µm thick. This thickness was suffi-
cient to provide a bending stiffness that prevented collapse 
of the mesh in solution. The thick nanofiber meshes were 
able to be wrapped tightly around a steel mandrel, and glued 
to form a tube (FIGS. 21B and C). Due to the fast curing 
time of the UV glue, it was localized to the overlapping 
edges and did not seep to the rest of the mesh. The perforated 
meshes held the tubular structure well, and the holes 
accounted for 10% of the total surface area of the mesh tube. 
The nanofiber mesh tubes were deformed slightly to place 
them around the native bone ends of the segmental defect, 
but they regained their original shape due to the elasticity of 
the mesh. The overlapping ends and the surrounding mus-
culature resulted in the tubes being stably located around the 
defect for the duration of the study (FIGS. 21D and E). In 
some samples that were taken down after one week, the 
alginate was found to be still present inside the tube lumen, 
even in perforated tubes, with hematoma formation at the 
a van Gieson counter stain (SURGIPATH Medical Inc., 
Richmond, Va., USA). This stain permits the detection of 
bone (pink), muscle (blue green) and cells (blue). 50 bone ends (FIG. 21F). 
Analysis of vascularity during bone regeneration. The 
vascular regrowth at the defect area was investigated at 3 
weeks post-surgery by using a modified version of the 
µCT-based angiography technique developed in our labora-
tory. After induction of anesthesia using isoflurane, a 25 55 
gauge catheter was introduced into the abdominal aorta and 
250 units (0.25 mL of 1000 units/mL) heparin were injected. 
The rat hind limb vasculature was cleared with PBS, fixed 
with 10% neutral buffered formalin and cleared again with 
PBS using a peristaltic pump (Masterflex, Cole-Parmer). 60 
The rats were euthanized by an overdose of isoflurane before 
the formalin perfusion. A radiopaque, lead chromate based 
contrast agent (Flow Tech, Carver, Mass.) was then injected 
and allowed to polymerize for at least two hours. The femur 
along with its musculature was excised carefully, fixed in 65 
10% neutral buffered formalin for 48 hours, and decalcified 
for 2 weeks using a formic acid based solution (Cal-Ex II, 
Alginate release kinetics. The in vitro release of rhMBP-2 
from alginate hydrogel plugs was monitored over a period of 
21 days (FIG. 21G). After dissolving the alginate plugs on 
day 0, 275.5±15.6 ng rhBMP-2 was detected in the resulting 
solution, indicating that the functional encapsulation per-
centage was 55.1 %. Of the amount encapsulated, 25.8% 
(71.2±3.8 ng) was released in the buffer solution in active 
form by day 21. The majority of the release took place 
within the first 7 days (98.6% of total released). The amount 
of rhBMP-2 retained in the gels was also assayed by 
dissolving them at day 21, and found that 9.9% (27.2±3.3 
ng) of the encapsulated amount was still present in the gels. 
It is possible that the binding of some of the rhBMP-2 
molecules to the alginate fibers masks the antibody binding 
site. This subset of rhBMP-2 molecules would not be 
detected by the ELISA, and therefore the actual amount of 
rhBMP-2 present in the hydrogels may be higher. 
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Radiographs. Two-dimensional radiographs were taken at 
4 and 12 weeks for qualitative assessment of bone healing 
(FIG. 22). Radiographs at the early time point of 4 weeks 
indicated that Groups I & II (Table 1) specimens had small 
amounts of bone formation, originating from the cut native 5 
ends and extending somewhat along the periphery. Group I 
samples were implanted with a nanofiber mesh tube alone, 
whereas Group II contained, in addition, alginate hydrogel 
inside the mesh tube. On the other hand, samples from 
Groups III and IV, in which 5-µg rhBMP-2 was delivered 10 
within alginate, demonstrated significant infiltration of min-
eralized tissue throughout the defect. Group IV specimens 
that were implanted with the perforated mesh tube exhibited 
the most robust mineralization. Group IV demonstrated the 
highest bridging rate (5/8) at the 4 week time point, whereas 15 
the remaining 3/8 defects were nearly bridged. Group III had 
none bridged, but 3/6 defects were nearly bridged. At 12 
weeks, Groups I and II had still not achieved osseous union 
in any specimen, with most of the bony tissue formed on the 
periphery. In contrast, all specimens in Groups III and IV 20 
were completely bridged with densely packed bone. 
In vivo µCT imaging. Animals were scanned in an in vivo 
µCT system at 4 and 12 weeks for quantifying bone forma-
tion (FIGS. 23A-C). The three-dimensional µCT images 
revealed that new bone formation in Groups III and IV 25 
occurred throughout the cross-section of the defect, whereas 
it appeared predominantly at the native bone margins and the 
periphery in Groups I and II (FIG. 23A). The analysis of 
regenerated bone volumes indicated that Groups III and IV 
(Table 1) had significantly more (a; p<0.05) bone formation 30 
in the defect compared to Groups I and II, at both time points 
(FIG. 23B). At 4 weeks, Group IV, implanted with the 
perforated mesh, had significantly more (b; p<0.05) bone 
formation than Group III, which contained the mesh tubes 
without holes. However at 12 weeks, there was no difference 35 
in bone volumes between Groups III and IV. There was a 
significant increase in bone volumes with time in Groups I 
(p=0.048), III (p<0.001) and IV (p=0.001), but not in Group 
II (p=0.08). Group III (37.65±2.22 mm3 ) samples demon-
strated the greatest increase in bone volume between 4 and 40 
12 weeks, followed by Group IV (20.02±2.96 mm3 ) Com-
pared to these two groups, Groups I (3.96±1.40 mm3 ) and II 
(2.09±0.80 mm3 ) had significantly less bone accumulation 
during the same period. 
The density of the newly formed bone within the defect 45 
was also calculated at 4 and 12 weeks (FIG. 23C). At 4 
weeks, Groups I and II contained higher density bone than 
Groups III and IV (b and c respectively; p<0.05). Group IV 
samples demonstrated a density higher than Group III, at 
both 4 and 12 weeks (b; p<0.05). There was a significant 50 
increase in density with time for all groups from 4 to 12 
weeks. 
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Histological analysis. Ground MMA sections were 
stained and analyzed for examining the regenerated tissue 
(FIGS. 25A and B). The nanofiber mesh tube was partially 
degraded due the MMA processing steps, but is still seen to 
be located around the defect. In Groups I and II, very little 
mineralized tissue was observed in the defect site at 12 
weeks, similar to the radiographic and µCT results (FIG. 
25A: I and II). The defects in these specimens were sparsely 
populated with fibrous tissue. The new bone formation was 
limited to the proximity of native bone ends and along the 
mesh tube. The end of the defects remained disconnected, 
with the capping of the native ends with bony tissue. The 
sections from Groups III and IV revealed extensive mineral 
deposition and bony bridging of the defects in these groups 
(FIG. 25A: III and IV). The newly formed bone was 
observed to be a combination of immature woven bone and 
mature lamellar bone. There was good continuity of the 
newly mineralized matrix with the native bone ends. Group 
IV, in particular, demonstrated the presence of a higher 
amount of lamellar bone, better integration at the native 
bone interface and development of marrow-like tissue. The 
dark areas correspond to undegraded alginate and the par-
tially degraded mesh. The higher magnification images of 
Groups III and IV indicated the presence of osteocytes 
embedded in lacunae and osteoblasts lining the new bone 
surfaces (FIG. 25B). Histological analysis performed at 4 
weeks revealed no evidence of cartilage tissue formation or 
endochondral ossification, indicating direct, intramembra-
nous bone formation within the alginate gel (data not 
shown). The density maps obtained from the µCT indicate 
good correlation with histology sections (data not shown). In 
addition, Group IV appeared to contain higher density 
mineralized tissue, which was distributed in a tubular pat-
tern, similar to that of native cortical structure. 
µCT-based angiography. Animals implanted with the 
rhBMP-2 containing Groups III and IV were euthanized at 
3 weeks post-implantation, and their hind limb vasculature 
perfused with a radiopaque contrast agent. The femur and 
the surrounding soft tissues were imaged using µCT to 
quantify vascular ingrowth at an early time point preceding 
bone regeneration. Contours were drawn to define two 
VOis. The first VOI included only the volume inside the 
defect region, whereas the second contained both the defect 
and the periphery of the defect, termed the total VOI (FIG. 
26). The analysis of the vasculature revealed the presence of 
vessels, both inside and outside the defect. The majority of 
the vascularity was observed in the periphery, as indicated 
by the significantly larger vessel volume in the total VOI (a; 
p<0.001). There were no significant differences in vascular 
volume between Groups III and IV, in either the defect or the 
total VOL 
This Example demonstrates a novel growth factor deliv-
ery technique for the functional repair of large bone defects 
using an electrospun nanofiber mesh tube and alginate 
hydrogel. Tubular scaffolds constructed from nanofiber 
meshes were placed around segmental defects. Alginate 
hydrogel containing 5-µg rhBMP-2 was injected into the 
tubes and constrained within the defect site by the mesh 
tube. The above results demonstrate that this technique 
results in substantial bone formation and complete defect 
bridging. Samples implanted with both perforated mesh tube 
and rhBMP-2 containing alginate had statistically equivalent 
biomechanical properties to those of intact age-matched 
femora, indicating functional restoration of the limb func-
Biomechanical properties. Torsional testing was per-
formed on extracted femora at 12 weeks to test their bio-
mechanical properties (FIG. 24). Age-matched non-operated 55 
femora were also tested to obtain properties of native intact 
bone. The maximum torque and stiffness in torsion was 
calculated from the torque-rotation data. Groups III and IV 
had significantly higher (a; p<0.01) maximum torque and 
stiffness compared to Groups I and II, as did the intact bone. 60 
There was no significant difference between Groups III and 
IV. However, compared to the intact bone, only Group IV 
samples had statistically equivalent maximum torque and 
stiffness, whereas Group III samples had significantly lower 
properties (b; p<0.05). The mechanical properties for Group 65 tion. 
IV were on average approximately 75% of those for intact 
bone. 
The majority of scaffolds proposed for bone reconstruc-
tion are structural scaffolds designed to support in vivo loads 
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and provide a three-dimensional framework for cell attach-
ment. They are examples of "hard scaffolds", usually made 
from slowly hydrolyzing polymers or ceramics with unpre-
dictable degradation. Though they provide a structure for 
tissue growth, it is difficult to fine-tune their degradation rate 
36 
formation at 4 weeks. However, by 12 weeks, the group 
without perforations (Group III) had comparable bone vol-
ume to the group with perforations (Group IV). The differ-
ences in the bone deposition rate between 4-12 weeks could 
be attributed to the fact that at week 4, Group IV defects 
were almost filled with newly formed bone, whereas Group 
III defects still exhibited substantial space for bone forma-
tion. Compared to Group III, the density of the newly 
formed bone was significantly higher in Group IV. Also, 
10 only Group IV femora demonstrated functional restoration 
of biomechanical properties. These results indicate that 
perforations in the nanofiber mesh tube expedited bone 
formation, resulting in advanced bone remodeling and 
to match the rate of tissue formation. The use of structural 
scaffolds also precludes the use of the intramedullary pin for 
limb fixation, a technique frequently used by orthopedic 
surgeons. In addition, the regular geometric shape of these 
scaffolds made them unsuitable to be placed inside fractures, 
which usually have irregular edges. Thin scaffold mem-
branes have also been used for bone repair in a procedure 
termed guided bone/tissue regeneration. In this technique, 
the membranes are positioned on the periosteal surface to 
provide a structure for bone formation. It has been argued 15 
that while 3-D scaffolds support the ingrowth of cells and 
tissue, the 2-D membranes may also protect the defect from 
soft tissue ingrowth and guide cell migration from the 
periosteum. Since the membranes are placed on the periph-
ery of the defect, they retain space for bone deposition 
throughout the defect. However, when a large mass of bone 
improved mechanical properties. 
There are two potential mechanisms that mediate the 
acceleration of bone formation due to perforations in our 
hybrid delivery system. The perforations may enhance inva-
sion of vascularity or improve osteoprogenitor cell migra-
tion from the surrounding soft tissues into the defect region. 
20 We initially hypothesized that perforations improve vascular 
invasion, and employed a µCT-based technique to quantita-
tively assess the vascularity in the early stages of bone 
regeneration. However, our results indicated that the perfo-
rations did not have a significant effect on vascularity at the 
is lost, repopulating the entire defect with cells would be a 
challenge due to the presence of a large void. 
Hydrogels are a class of highly hydrated materials that 
enable cellular and tissue infiltration with relative ease. 
Alginate hydrogels are an example of such a "soft scaffold" 
that can deployed using minimally invasive procedures, 
conform to the shape of the defect and be manipulated by 
cells during tissue regeneration. In addition, they can be 
used for sustained delivery of osteoinductive growth factors, 
a typical requirement for healing large defects. The primary 
concern with hydrogels is their inadequate mechanical stiff-
ness, which causes them to deform easily under load. 
Discussion. In this Example, we present a novel hybrid 
technique that utilizes both a nanofiber mesh membrane and 
an alginate hydrogel. The mesh tubes prevent soft tissue 
invagination into the defect and create a space for tissue 
regeneration. In addition, they potentially guide the migra-
tion of progenitor cells along the periosteal surface, and 
retain the osteogenic factors within the defect site. However, 
nanofiber mesh tubes, alone or in presence of alginate 
hydrogel without rhBMP-2, were not sufficient to bridge the 
8 mm segmental defects in rat femora. Without the presence 
of the osteoinductive protein, the center was only sparsely 
populated by cells and bony tissue capped the ends of the 
defect. 
The above results illustrate higher bone formation with 
the sustained release of rhBMP-2 from the alginate hydro-
gel. All defects in the rhBMP-2 groups (Groups III and IV) 
were bridged by 12 weeks with densely packed, cell medi-
ated mineralized tissue. This suggests that the release of 
rhBMP-2 is able to attract osteoprogenitor cells into the 
defect from the adjacent periosteum, marrow and vascular-
ized tissues, and induce them to undergo osteogenic differ-
entiation. The release of proteins from alginate occurs due to 
25 defect site. In addition, it was seen that only a fraction of the 
total vessels were present inside the defect. It is possible that 
the scan resolution was too low to detect the microvascu-
lature in the developing bone. The lack of differences in 
vascular regrowth due to the perforations suggests that the 
30 acceleration of bone formation was due to improved osteo-
progenitor cell migration into the defect. 
The current clinical technique for rhBMP-2 delivery 
involves soaking a collagen sponge with rhBMP-2 solution, 
which primarily relies on the adsorption of the protein to 
35 collagen. Numerous sustained delivery systems are being 
currently developed from natural and synthetic materials for 
reducing the high rhBMP-2 dose required clinically. By 
providing a sustained and localized release ofrhBMP-2 and 
permitting robust cell infiltration, the hybrid alginate/nano-
40 fiber mesh system creates an environment conducive for 
bone regeneration. The 5-µg dose utilized in this study is in 
the lower range of what has been reported (2-20 µg) in 
similar models. For example, in a 8 mm rat segmental defect 
model, 20-µg of rhBMP-2 delivered on inactive demineral-
45 ized bone matrix was required for defect bridging. 
In conclusion, a novel hybrid growth factor delivery 
system was presented in this Example. This system resulted 
in complete bony bridging of challenging segmental bone 
defects in a rat model. Perforations accelerated the deposi-
50 tion of mineralized tissue, and resulted in functional repair, 
by perhaps improving osteoprogenitor cell migration into 
the defect. The mesh tube alone, or in combination with 
alginate hydrogel, did not generate a strong repair response. 
The sustained delivery of rhBMP-2 via alginate hydrogel 
55 was required for substantial regeneration to occur. These 
results indicate that this hybrid technique may be clinically 
useful for bone regeneration in the case of fracture non-
unions and large bone defects. 
a combination of diffusion and gel degradation. It is inter-
esting to note that after 21 days, at least 10% of the 
functionally encapsulated rhBMP-2 was still present in the 
alginate, though the amount of the protein released at this 
time point was negligible. This suggests that a portion of the 60 
protein binds to the alginate polymer, which at later time 
points may be available to the invading cells. 
Example 4 
Delivery of Bone Morphogenetic Protein within 
Nanofiber Mesh/Alginate Enhances Segmental 
Bone Defect Repair 
The presence of perforations in nanofiber mesh tubes 
accelerated early bone formation and defect bridging. The 
utilization of in vivo µCT scanning techniques permitted the 65 
sequential scanning of animals at multiple time points, and 
revealed that perforations in mesh tubes enhanced bone 
The purpose of this study was to compare the hybrid 
nanofiber mesh/alginate BMP delivery technique with the 
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clinical standard of BMP delivery on collagen matrix. In 
addition, the role of the nanofiber mesh tube as a spatial 
constraint was investigated. Our hypotheses were that BMP 
delivery within alginate hydrogel would enhance bone for-
mation, and that the mesh tube would aid in the spatial 
retention of the regenerated bone. To test this hypothesis, we 
evaluated the structural and biomechanical properties of the 
regenerated bone in a challenging rat segmental defect 
model. 
Materials and Methods 
Nanofiber mesh tube fabrication and alginate preparation. 
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properties. Maximum torque and failure angle were mea-
sured at the failure point from the torque-rotation data, and 
the work to failure was calculated using these values. 
Torsional stiffness was calculated by fitting a straight line to 
the linear portion of the curve before failure. Histological 
analysis was also performed at 12 weeks by embedding 
decalcified femurs in glycol methacrylate (GMA) and stain-
ing 5 µm sections with H&E. 
Data analysis. Data are presented as mean±standard error 
10 of mean (SEM). Data were analyzed using ANOVA and 
Tukey's tests for pairwise comparisons (significance set at 
p<0.05). When data were not normal, the nonparametric 
Mann-Whitney test was used to compare between groups. 
Minitab 15 (Minitab Inc., State College, Pa.) was used for all 
Nanofiber meshes were made by electrospinning and formed 
into tubes as described in Example 4. Briefly, a 12% (w/v) 
solution of poly (E-caprolactone) (PCL) was made by dis-
solving the polymer in a 90: 10 volume ratio of hexafluoro-
2-propanol:dimethylformamide. The following parameters 
were used during electrospinning: flow rate: 0.75 mL/hr; 
voltage: 13 kV; collector distance: 17 cm; needle gauge: 22. 
Fibers were collected for 6 hours to obtain nanofiber meshes 
having a thickness of approximately 300-400 µm. Perfora- 20 
tions measuring 1 mm in diameter and spaced approximately 
15 statistical analysis. 
Group 
Group I 
Group II 
Group III 
TABLE 2 
Description 
Collagen scaffold+ 5 µg rhBMP-2 
Alginate scaffold + 5 µg rhBMP-2 
Perforated nanofiber mesh tube + Alginate + 
5 µg rhBMP-2 
1.5 mm apart were made in rectangular 13x19 mm mesh 
samples using a biopsy punch. The mesh samples were 
wrapped around a steel mandrel and glued using UV glue 
(DYMAX Corporation, Torrington, Conn.) to form hollow 25 
tubular implants having a diameter of approximately 5 mm 
and 13 mm length. 
Results 
Radiographs. The radiographs at the early time point of 2 
weeks illustrated that, while considerable new bone depo-
sition was evident in the collagen scaffold group (Group I), 
the alginate groups (Groups II and III) demonstrated com-
paratively less bone formation (FIG. 27). In contrast, the 
radiographs at 4 and 12 weeks revealed that the alginate 
Medical grade alginate, MVG (FMC Biopolymer, Phila-
delphia, Pa.), was irradiated with a 5 Mrad dose of Gamma 
irradiation, and covalently coupled with RGD-containing 30 
G4RGDAS SP peptide sequences. Alginate hydrogels, 
encapsulating 33.33 µg/mL rhBMP-2, were prepared in 1 
mL syringes at a concentration of 2% (w/v) by crosslinking 
the alginate with calcium sulfate slurry (Chapter 5). For one 
groups exhibited higher amount of bone, though there was 
substantial bone regeneration in all groups at 4 weeks and 
bridging of all defects after 12 weeks. In addition, there were 
differences in the distribution and density of bone deposition 
among groups. Group I samples appeared to have more 
of the experimental groups, the hydro gels were made in the 35 
form of cylindrical plugs ( cp5 mm; 9 mm length) by using a 
custom built mold. trabecular-like bone that was not as densely packed as the 
other two groups. Group II demonstrated mineral deposition 
both within and outside the defect, suggesting some alginate 
Animal model and bone regeneration analysis. Femora of 
13 week old female Sasco Sprague-Dawley rats were sta-
bilized with custom fixation plates. Bilateral 8 mm segmen-
tal defects were created in the mid femoral diaphyses with 
an oscillating saw under irrigation. A 5 µg dose of rhBMP-2 
was delivered to each defect in one of three different ways 
shown in Table 2. In Group I, a collagen scaffold (cp5 mm; 
9 mm length) was soaked with 150 µL of 33.33 µg/mL 
rhMBP-2 solution for 15 minutes, and implanted in the 
defect. The collagen scaffolds were obtained from a fibrous 
collagen sheet (average pore size 61.7 µm, 93.7% pore 
volume, Kensey Nash, Exton, Pa.). Group II implants con-
sisted of a cylindrical scaffold ( cp5 mm; 9 mm length) made 
from alginate containing 5 µg rhBMP-2. In Group III, 
perforated nanofiber mesh tubes were placed around the 
defect, and injected with 5 µg rhBMP-2-containing alginate 
using a 22 g needle. 
Radio graphs and µCT images of 8-10 samples per group 
were obtained at 4 and 12 weeks to assess bone formation. 
Radiographs were also taken at 2 weeks to assess early 
differences between groups. In addition to the volume of 
newly formed bone at each time point, µCT data was 
processed to obtain mean density, connectivity density and 
temporal changes in volume of the regenerated bone. Based 
on the two dimensional scan slices, an appropriate threshold 
was selected at each time point to detect new bone forma-
tion. 
Torsional testing was performed on extracted femurs at 12 
weeks using a Bose ElectroForce system (ELF 3200, Bose 
EnduraTEC, Minnetonka, Minn.) to test their biomechanical 
40 scaffold displacement or protein diffusion. In contrast, 
samples in Group III exhibited consistent localization of 
dense new bone formation inside the defect. 
µCT analysis. The three-dimensional µCT images 
obtained in vivo at 4 and 12 weeks were consistent with the 
45 radiographs (FIG. 28). The collagen scaffold group (Group 
I) demonstrated substantial bone formation in the defects by 
4 weeks. Specimens in the alginate scaffold group (Group II) 
exhibited a fragmented distribution of mineralized tissue, 
with substantial bone formation occurring outside the defect 
50 region. In contrast, in the presence of a nano fiber mesh tube 
(Group III), new bone formation was confined within the 
defect region and displayed a continuous distribution. 
µCT analysis determined that the amount and distribution 
of regenerated bone was significantly affected by the 
55 rhBMP-2 delivery method. Two volumes of interest (VOI) 
were defined for the quantitative analysis of bone distribu-
tion. The central VOI corresponds to an interior cylindrical 
volume that captures the defect. The total VOI contains the 
entire volume of mineralization, in and around the defect, 
60 including the irregular bone formation outside the defect. At 
both 4 and 12 weeks, the alginate delivery groups (Groups 
II and III) had significantly more bone formation than the 
collagen delivery groups (Group I) (FIG. 29A). The bone 
volume in the central VOI at 4 weeks was not significantly 
65 higher in Group II compared to Group I; however the p value 
was very close to significance (p=0.051). Although there 
was no difference between Groups II and III at 4 weeks, the 
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central VOI analysis at 12 weeks revealed a significant 
increase in bone formation within the defect region associ-
ated with use of the nanofiber mesh tube (Group III). 
However, it was observed that the total bone volume at 12 
weeks was not significantly different between Groups II and 
III. The change in bone volume between 4 and 12 weeks was 
calculated for each specimen (FIG. 29B). This analysis 
demonstrated that Group III specimens had the largest 
mcrease in mineral accumulation between the two time 
points. 
40 
formation that was seen in the total VOL However, the 
pattern of bone formation that was observed in the alginate 
group without the mesh tube (Group II) indicated substantial 
bone formation outside the defect region, which implies 
leakage of the hydrogel and/or protein to the surrounding 
area. Analysis of the central VOI, which excluded this 
abnormal bone formation, revealed that presence of the 
nanofiber mesh tube (Group III) indeed enhanced bone 
formation within the defect region. This indicates that the 
10 nanofiber mesh tube is able to improve the spatial retention 
of rhBMP-2 within the defect by containing the alginate 
and/or the growth factor. 
Mean density and connect1v1ty density of the newly 
formed bone were evaluated at 4 and 12 weeks (FIG. 30). 
The results indicate that the mean bone density in Group III 
specimens was significantly lower than those in Groups I 
and II, at both time points and in both VO Is. There was more 15 
than a 50% increase in the density of all groups between 4 
and 12 weeks, indicating maturation of the mineralized 
tissue. At 4 weeks, the connectivity density in Group III was 
significantly higher than the other two groups, though there 
were no differences at 12 weeks. Finally, it was observed 20 
that the newly formed bone in the central VOI displayed 
higher connectivity density than that contained in the total 
VOL 
Differences due to the BMP delivery method were 
observed in mineral deposition rate, as well as mineral 
density and biomechanical properties of the regenerated 
bone. Mineral accumulation between 4 and 12 weeks was 
highest for specimens in the hybrid delivery group (Group 
III), even higher than the alginate group without the mesh 
tube (Group II). This suggests that presence of the nanofiber 
mesh tube improves localization of rhBMP-2 within the 
defect site for a longer time period. It is possible that the 
nanofiber mesh tube slows the protein diffusion away from 
the implant, by perhaps binding the protein through non-
specific interactions. In an in vitro study, we observed that Biomechanical properties. Biomechanical properties of 
the regenerated femurs were obtained from torsional testing 
at 12 weeks. The maximum torque was 58% higher for 
Group III (alginate+mesh) specimens, compared to Group I 
(collagen) specimens (FIG. 31). In addition, the torsional 
stiffness and work to failure of Group III specimens were 
significantly higher than those in Group I by 58% and 102%, 
respectively. Though the value of mean failure angle was 
largest in the case of Group III, there were no significant 
differences between the groups Importantly, there were no 
differences in the biomechanical properties between Groups 
I (collagen) and II (alginate). There were no significant 
differences in any of the mechanical parameters between 
Groups II and III; however the mean values of all parameters 
were higher for Group III specimens. 
Discussion. This Example quantitatively compares a 
novel hybrid BMP delivery system to the current clinical 
standard for challenging bone defect repair. Compared to 
delivery on a collagen matrix, rhBMP-2 delivered at the 
same dose via alginate hydrogel resulted in enhanced bone 
formation as early as four weeks. The addition of a perfo-
rated nanofiber mesh to spatially retain the BMP hydrogel 
resulted in an increased mineral accumulation between 4 and 
12 weeks, leading to enhanced bone ingrowth into the defect 
region at 12 weeks, compared to all other groups. Finally, 
biomechanical function was significantly improved follow-
ing treatment with the hybrid nanofiber mesh/hydrogel 
delivery system, compared to collagen matrix delivery. 
The amount and distribution of newly formed bone was 
influenced by the BMP delivery method. At two weeks, there 
appeared to a greater amount of mineral deposition with the 
collagen matrix delivery (Group I), compared to the alginate 
delivery (Groups II and III). However, by 4 weeks, the 
alginate groups demonstrated higher bone volume than the 
collagen matrix delivery, and this trend continued at 12 
weeks. These results indicate that the kinetics of bone repair 
is dependent on the delivery system. This suggests that, 
whereas a majority of rhBMP-2 was released from the 
collagen matrix by 2 weeks, protein retention at the defect 
site beyond 2 weeks was improved with alginate hydrogel 
delivery. This is consistent with other studies that report that 
less than 5% of rhBMP-2 is retained within a collagen 
sponge by 2 weeks in vivo. Addition of the nanofiber mesh 
tube to the alginate hydrogel did not enhance overall bone 
25 overnight incubation of a nanofiber mesh sample with a 
model protein, ovalbumin, resulted in 90% of the protein 
bound to the mesh, which remained attached to the mesh 
even at 1 week (data not shown). As the surface area of the 
nanofiber mesh is relatively large, these interaction effects 
30 may have a substantial effect on protein retention. Alterna-
tively, the nano fiber mesh tube may function by constraining 
and therefore compacting the BMP-containing hydrogel, 
which could improve the local retention at later time points. 
In contrast to mineral accumulation, the density of the 
35 mineralized tissue was lowest in Group III. This suggests 
that new, immature bone is still being laid down in Group III 
specimens at later time points, which lowers the overall bone 
density in this group. It should be noted that the density 
obtained from the µCT is the actual density of the bone 
40 tissue, and not the apparent density of the entire bone.This 
would explain the lower tissue density in Group III speci-
mens, even though the regenerated bone in these specimens 
appeared denser in the radiographs. In spite of the lower 
tissue density, maximum torque, torsional stiffness and work 
45 to failure were significantly higher in Group III specimens, 
when compared to those in Group L This indicates that the 
higher bone volume in Group III compensated for the lower 
mineral density in contributing to the biomechanical prop-
erties. It should be noted that the Group III torsional 
50 properties exceeded those of age-matched intact femurs 
determined previously (Chapter 5). For example, the mean 
maximum torque of Group III samples was observed to be 
0.44 Nm, whereas it was 0.31 Nm in the case of intact 
femurs. There were no significant differences in the biome-
55 chanical properties between Groups II and III; however the 
mean values were consistently higher for Group III speci-
mens. This suggests that, although there was significantly 
higher mineralization in Group III inside the defect region, 
the bony tissue outside the defect in Group II contributed 
60 somewhat to the overall mechanical properties. 
The connectivity of the regenerating bone was also 
affected by the protein delivery system. Connectivity density 
is a parameter used to analyze trabecular bone, and is a 
measure of the number of trabeculae in a unit volume. 
65 Though regenerating bone does not consist of mature tra-
beculae, the direct mineralization induced by BMPs is 
initiated at discrete locations, which then develop connec-
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tions as the mineralization progresses. The connectivity 
obtained from the µCT analysis of regenerating bone is a 
measure of these connections. At 4 weeks, Group III speci-
mens demonstrated the highest connectivity density, com-
pared to the other two groups, indicating a more intercon-
nected bone structure, perhaps because of the spatial 
guidance provided by the alginate hydrogel and the contain-
ment effect of the nano fiber mesh tube. Containment due to 
42 
What is claimed is: 
1. A system for affecting an anatomical structure having 
a fillable space, the system comprising 
a nanofiber mesh configured to substantially conform to 
an external surface of the anatomical structure, wherein 
at least a portion of the nanofiber mesh delineates a 
boundary between a milieu surrounding the anatomical 
structure and the fillable space of the anatomical struc-
ture and further comprising an injectible, flowable 
carrier substance substantially filling the fillable space 
of the anatomical structure. 
2. The system for affecting an anatomical structure of 
claim 1, further comprising an active agent. 
the mesh tube may have facilitated connection of the min-
eralized nodes formed during intramembranous ossification. 10 
There were no differences in connectivity density at 12 
weeks, and the values were uniformly low. This could be due 
3. The system for affecting an anatomical structure of 
claim 1, wherein the nanofiber mesh has an average pore 
15 size of less than about 100 micrometers. 
to the fact that as the defect fills with bony tissue, the 
discrete bone initiation centers merge to form a continuous 
volume, which would reduce the connectivity density. 
The results of this Example demonstrate that delivery of 
rhBMP-2 via the hybrid nanofiber mesh/alginate system 
results in improved bone repair compared to delivery on a 
collagen matrix, the technique currently used by orthopaedic 20 
surgeons. Delivery of BMPs on collagen matrix has been 
shown to result in significant initial burst release, in the 
range of 40-90%. In the in vitro release of Example 3, 
approximately 10% of the encapsulated rhBMP-2 remains 
attached to alginate after 3 weeks, though the amount 25 
released in the media was negligible at this time point. This 
suggests that the protein binds to the alginate matrix and 
may be available to invading progenitor cells at later time 
points, which would mean that the function of the alginate 
hydrogel is more to improve long term availability than 30 
sustained release. Binding of the protein by alginate may be 
advantageous by protecting it from degradation. These 
results also suggest that the nanofiber mesh tube may aid in 
containing the exogenous growth factor within the defect 35 
region. 
The delivery of BMPs on collagen matrix has been tested 
4. The system for affecting an anatomical structure of 
claim 1, wherein the nanofiber mesh further comprises a 
plurality of macropores. 
5. The system for affecting an anatomical structure of 
claim 2, wherein the active agent comprises at least one 
member of the transforming growth factor beta superfamily. 
6. The system for affecting an anatomical structure of 
claim 5, wherein the carrier substance comprises a hydrogel. 
7. The system for affecting an anatomical structure of 
claim 6, wherein the anatomical structure is bone, and 
wherein the carrier substance comprises alginate or a deriva-
tive thereof, and wherein the at least one member of the 
transforming growth factor beta superfamily comprises a 
bone morphogenetic protein. 
8. The system for affecting an anatomical structure of 
claim 7, wherein the active agent further comprises a plu-
rality of mesenchymal progenitor cells. 
9. A kit for affecting an anatomical structure having a 
fillable space, the kit comprising: 
a nanofiber mesh configured to substantially conform to 
an external surface of the anatomical structure, wherein 
at least a portion of the nanofiber mesh delineates a 
boundary between a milieu surrounding the anatomical 
structure and the fillable space of the anatomical struc-
ture; and 
a flowable hydrogel system comprising at least one active 
agent, wherein the flowable hydrogel system is injected 
into and substantially fills the fillable space of the 
anatomical structure. 
in a number of animal models of large bone defect repair; 
however high protein doses are typically required. For 
instance, it has been reported that delivery of 10 µg 40 
rhBMP-2 (double the dose used in this study) resulted in 
bony bridging of a 6 mm rat segmental defect, which is less 
challenging than the 8 mm defect utilized in this Example. 
The injection of 5 µg rhBMP-2 in this Example is equivalent 
to a 20 µg/kg dose, which is around 1/s'h the clinical dose 
used in humans. It should be noted that sensitivity to 
rhBMP-2 varies with species; however our dose is still low 
compared to that used in similar models. By maintaining 
sustained and localized availability of rhBMP-2, the hybrid 
alginate/nanofiber mesh system could result in functional 50 
bone restoration at a lower dose, thereby reducing the cost 
and complications associated with collagen matrix delivery. 
10. The kit for affecting an anatomical structure of claim 
45 9, wherein the nanofiber mesh has an average pore size of 
less than about 100 micrometers. 
In conclusion, this study provides promising evidence in a 
challenging small animal model that spatiotemporal delivery 
strategies may enhance the therapeutic efficacy of BMP for 
repair of large bone defects. 
11. The kit for affecting an anatomical structure of claim 
10, wherein the nanofiber mesh further comprises a plurality 
of macropores. 
12. The kit for affecting an anatomical structure of claim 
10, wherein the anatomical structure is bone, and wherein 
the flowable hydrogel comprises alginate or a derivative 
thereof, and wherein the active agent comprises a bone 
morphogenetic protein. 
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